Illuminating Cancer's Hidden Landscape: NIR-II Probes for Deep-Tissue Visualization of the Tumor Microenvironment

Abstract

This comprehensive article explores the transformative role of second near-infrared window (NIR-II, 1000-1700 nm) fluorescence probes in visualizing the dynamic tumor microenvironment (TME). We begin by establishing the fundamental principles of NIR-II imaging, explaining why this spectral window offers superior resolution, depth, and signal-to-noise ratios for in vivo studies compared to traditional NIR-I. We then detail the design, synthesis, and functionalization strategies for current and emerging NIR-II probes, including organic dyes, quantum dots, and rare-earth nanoparticles, tailored for targeting specific TME components like vasculature, hypoxia, acidosis, and immune cells. Practical methodologies for probe administration, imaging protocols, and data analysis are discussed, followed by a critical troubleshooting guide addressing common challenges such as photobleaching, biodistribution, and nonspecific uptake. Finally, we present a comparative analysis of leading NIR-II probe platforms, validating their performance against established imaging modalities like MRI and PET, and assessing their specificity and sensitivity. This guide provides researchers, scientists, and drug developers with the knowledge to select, apply, and optimize NIR-II imaging for advancing precision oncology and therapeutic monitoring.

Beyond the Surface: The NIR-II Revolution in Tumor Microenvironment Imaging

Application Notes

The tumor microenvironment (TME) is a complex and dynamic ecosystem that surrounds and supports a tumor, playing a critical role in cancer progression, metastasis, and therapy resistance. For researchers utilizing NIR-II (1000-1700 nm) fluorescence imaging probes, precise anatomical and functional mapping of the TME is paramount. This technology offers superior tissue penetration and reduced autofluorescence, enabling real-time, high-resolution visualization of TME components and their interactions in vivo. Defining and targeting the TME's key elements is essential for developing next-generation diagnostics and therapeutics.

Cellular Components of the TME

The cellular compartment consists of both malignant cells and a diverse array of recruited and resident host cells.

• Cancer Cells: The originators, characterized by heterogeneity, genetic instability, and reprogrammed metabolism. They secrete signals to shape the TME.
• Cancer-Associated Fibroblasts (CAFs): Activated stromal cells that constitute a major fraction of the TME. They remodel the extracellular matrix (ECM), secrete growth factors/cytokines, and suppress anti-tumor immunity.
• Immune Infiltrates:
  • Myeloid-derived Suppressor Cells (MDSCs), Tumor-Associated Macrophages (TAMs): Predominantly pro-tumorigenic, promoting immunosuppression, angiogenesis, and metastasis.
  • T Lymphocytes: Include both effector CD8+ cytotoxic T cells (desired for anti-tumor response) and regulatory T cells (Tregs) that suppress immunity.
  • Tumor-Associated Neutrophils (TANs): Can exhibit anti-tumor (N1) or pro-tumor (N2) phenotypes.
• Endothelial Cells: Form the tumor vasculature, which is often aberrant, leaky, and disorganized, contributing to hypoxia and increased interstitial fluid pressure.

Non-Cellular Components of the TME

This acellular matrix provides structural and biochemical support.

• Extracellular Matrix (ECM): A network of proteins (collagen, fibronectin, laminin) and polysaccharides (hyaluronic acid) that is constantly remodeled in tumors, increasing stiffness and creating barriers to drug delivery.
• Soluble Factors: Includes cytokines (e.g., TGF-β, IL-10), chemokines (e.g., CXCL12), growth factors (e.g., VEGF), and enzymes (e.g., matrix metalloproteinases - MMPs).
• Physical Conditions: Hypoxia (low oxygen) is a hallmark, driving genetic instability and therapy resistance. Acidosis results from upregulated glycolysis (Warburg effect).

Table 1: Prevalence and Key Markers of Major Cellular Components in Solid Tumors

Component	Typical % of TME (Range)*	Key Phenotypic/Functional Markers	Pro-Tumor Role
Cancer-Associated Fibroblasts (CAFs)	15-80%	α-SMA, FAP, PDGFRβ, Vimentin	ECM remodeling, immunosuppression, metabolic reprogramming
Tumor-Associated Macrophages (TAMs)	5-40%	CD68, CD163, CD206, ARG1	Angiogenesis, metastasis, T-cell suppression
Cytotoxic T Lymphocytes (CTLs)	0-10% (variable)	CD8+, CD3+, Granzyme B, IFN-γ	Anti-tumor cytotoxicity (often dysfunctional)
Myeloid-Derived Suppressor Cells (MDSCs)	5-30%	CD11b+, Gr-1+ (mouse), CD33+, HLA-DR- (human)	Broad immunosuppression, promoting metastasis
Regulatory T Cells (Tregs)	5-25% (of T-cells)	CD4+, CD25+, FOXP3+	Suppression of effector T-cell function

*Percentages are highly tumor-type and stage-dependent. Data synthesized from recent tumor profiling studies.

Table 2: Key Non-Cellular Components and Their Tumor-Promoting Functions

Component	Key Subtypes/Examples	Primary Tumor-Promoting Functions
Extracellular Matrix (ECM)	Collagen I/III/IV, Fibronectin, Hyaluronan, Laminin	Creates physical barrier, increases interstitial pressure, activates pro-survival signaling
Soluble Signaling Factors	VEGF, TGF-β, CXCL12, IL-6, IL-10	Angiogenesis (VEGF), immunosuppression (TGF-β, IL-10), cell recruitment (CXCL12)
Enzymes	Matrix Metalloproteinases (MMPs 2, 9), LOX	ECM degradation (invasion), ECM cross-linking (stiffness)
Physical Conditions	Hypoxia (pO2 < 10 mmHg), Acidosis (pH ~6.5-6.9)	Drives genomic instability, selects for aggressive clones, inhibits immune cell function

Protocols for TME Analysis with NIR-II Imaging Integration

Protocol 1: Multiplexed In Vivo NIR-II Imaging of TME Vasculature and pH

Objective: To simultaneously visualize tumor vasculature architecture and the acidic pH of the TME in a live mouse model.

Materials: See "The Scientist's Toolkit" below.

Procedure:

• Tumor Model Preparation: Implant relevant cancer cells (e.g., 4T1, CT26) subcutaneously into athymic or immunocompetent mice. Allow tumors to grow to ~100-200 mm³.
• Probe Administration: Prepare a cocktail of NIR-II probes:
  • Inject IRDye 800CW PEG (or similar non-targeted NIR-II vascular agent) at 2 nmol in 100 µL PBS via tail vein.
  • Inject pH-sensitive NIR-II probe (e.g., CH1055-PEG-pH) at 1.5 nmol in 100 µL PBS via tail vein.
• NIR-II Imaging:
  • Anesthetize the mouse using isoflurane (2% in oxygen).
  • Place the mouse in the NIR-II fluorescence imaging system.
  • Acquire baseline images pre-injection.
  • Acquire time-series images at 1, 5, 15, 30, 60, 120, and 240 minutes post-injection. Use appropriate laser excitation and emission filters for each probe (e.g., 808 nm excitation, 1000 nm long-pass filter for CH1055).
• Data Analysis:
  • Use software to separate channels based on spectral unmixing or distinct emission windows.
  • Quantify vascular parameters (total flux, vessel tortuosity) from the vascular probe channel.
  • Generate a ratiometric pH map by calculating the ratio of fluorescence intensities from the pH-sensitive probe at two emission wavelengths (if applicable) or over time as the probe accumulates in acidic regions.

Protocol 2: Ex Vivo Immunofluorescence Staining for CAFs and TAMs Post NIR-II Imaging

Objective: To validate in vivo NIR-II imaging findings with high-resolution, spatially resolved ex vivo analysis of key stromal cells.

Procedure:

• Terminal Procedure & Tissue Harvest: Following the final in vivo NIR-II imaging time point, euthanize the mouse. Excise the tumor and immediately place it in OCT compound. Freeze on dry ice or in a -80°C isopentane bath. Store at -80°C.
• Cryosectioning: Cut 8-10 µm thick sections using a cryostat. Mount on Superfrost Plus slides. Air dry for 30 minutes. Fix in cold acetone for 10 minutes at -20°C. Air dry.
• Immunofluorescence Staining:
  • Rehydrate slides in PBS for 5 min.
  • Block with 5% normal donkey serum in PBS with 0.3% Triton X-100 for 1 hour at RT.
  • Incubate with primary antibody cocktail overnight at 4°C in a humidified chamber.
    • Anti-α-SMA (1:200, CAF marker)
    • Anti-F4/80 or CD68 (1:100, macrophage marker)
    • Anti-Collagen I (1:200, ECM marker)
  • Wash 3 x 5 min with PBS.
  • Incubate with appropriate secondary antibodies conjugated to fluorophores (e.g., Alexa Fluor 488, 555, 647) for 1 hour at RT in the dark.
  • Wash 3 x 5 min with PBS.
  • Counterstain nuclei with DAPI (300 nM) for 5 min.
  • Wash and mount with antifade mounting medium.
• Confocal Microscopy & Correlation: Image sections using a confocal microscope. Overlay fluorescence channels to assess co-localization. Correlate the spatial distribution of CAFs (α-SMA+) and TAMs (F4/80+) with regions of high NIR-II probe signal from previous in vivo imaging.

Diagrams

TME Crosstalk and NIR-II Targeting

NIR-II TME Imaging & Validation Workflow

The Scientist's Toolkit: Key Reagents for NIR-II TME Imaging

Table 3: Essential Research Reagents and Materials

Item	Example/Product Code	Function in TME/NIR-II Research
NIR-II Vascular Probe	IRDye 800CW PEG, CH1055-PEG	Non-targeted agent for visualizing tumor vasculature architecture and permeability.
NIR-II pH-Sensitive Probe	CH1055-PEG-pH, other rationetric pH probes	Reports on the acidic extracellular pH of the TME, a key physical hallmark.
NIR-II Targeted Probe	Anti-FAP Antibody conjugated to NIR-II dye (e.g., IRDye 12N3)	Specifically labels Cancer-Associated Fibroblasts (CAFs) for cellular-level TME mapping.
In Vivo Imaging System	NIR-II Fluorescence Imager (e.g., from In-Vivo Analytics)	Equipment capable of >1000 nm detection for deep-tissue, high-resolution imaging.
Anti-α-SMA Antibody	Abcam ab5694	Primary antibody for identifying activated CAFs in ex vivo validation.
Anti-F4/80 Antibody	BioLegend 123102	Primary antibody for identifying total macrophages in mouse tissue.
Anti-CD68 Antibody	Abcam ab955	Primary antibody for identifying human macrophages.
Fluorophore-conjugated Secondary Antibodies	Alexa Fluor 488/555/647	Enable multiplex immunofluorescence staining for correlative microscopy.
Cryo-embedding Medium	OCT Compound (Tissue-Tek)	Preserves tissue morphology for frozen sectioning post-imaging.
Matrigel (Growth Factor Reduced)	Corning 356231	For orthotopic or co-injection tumor models to study stromal interactions.

Within the broader thesis on developing advanced NIR-II probes for visualizing the dynamic tumor microenvironment, understanding the fundamental optical physics is paramount. The second near-infrared window (NIR-II, 1000-1700 nm) offers transformative advantages over traditional NIR-I (700-900 nm) and visible light imaging for deep-tissue applications. This shift is driven by significantly reduced scattering and autofluorescence, leading to unparalleled improvements in penetration depth, spatial resolution, and signal-to-background ratio.

Quantitative Comparison of Optical Windows

The superiority of the NIR-II window is quantitatively demonstrated by key optical properties in biological tissue.

Table 1: Optical Properties of Light in Biological Tissue Across Spectral Windows

Spectral Window	Wavelength Range (nm)	Scattering Coefficient (μs')	Absorption by Hb/H2O	Autofluorescence	Typical Penetration Depth (mm)	Achievable Resolution (μm) at 3mm depth
Visible	400-700	Very High	High	Very High	<1	>500
NIR-I	700-900	High	Moderate	High	1-2	~100-200
NIR-IIa	1000-1300	Low	Low (Hb falls)	Negligible	3-8	~20-50
NIR-IIb	1300-1700	Very Low	Higher (H2O rises)	None	2-5 (optimal 1300-1400 nm)	<20

Data synthesized from current literature (Zhou et al., Nat. Photonics, 2023; Hong et al., Chem. Rev., 2022). Key finding: The 1000-1300 nm sub-window offers the optimal balance of low scattering and minimal water absorption.

Core Physics: Reduced Scattering & Absorption

The primary physical principles enabling deeper penetration are:

• Reduced Scattering: Light scattering in tissue, dominated by Mie scattering, decreases proportionally to λ^-γ (where γ ≈ 0.2-2.4 for biological tissues). Longer wavelengths encounter fewer scattering events, maintaining a more ballistic photon path.
• Minimized Absorption: The absorption coefficients of major tissue chromophores (oxy/deoxy-hemoglobin, lipids) reach a local minimum between 650-900 nm but rise again. Critically, in the 1000-1350 nm range, hemoglobin absorption is negligible, and water absorption remains low, creating an "optical transparency window."

Diagram Title: NIR-II Physics: From Reduced Photon-Tissue Interaction to Superior Imaging Outcomes

Experimental Protocols for NIR-II Imaging in Tumor Microenvironment

Protocol 4.1: In Vivo NIR-IIb Imaging of Tumor Vasculature

Objective: To achieve high-resolution, deep-tissue imaging of tumor angiogenesis using a 1550 nm emitting probe. Materials: See "The Scientist's Toolkit" below. Procedure:

• Animal Model Preparation: Inoculate 1x10^6 tumor cells (e.g., 4T1, U87-MG) subcutaneously into the flank of an athymic nude mouse. Proceed with imaging when tumor volume reaches 100-150 mm³.
• Probe Administration: Dilate the mouse tail vein using a warming box. Inject 200 µL of CH-105T PEGylated probe (100 µM in sterile PBS) via tail vein catheter.
• Imaging System Setup: a. Anesthetize the mouse using 2% isoflurane in oxygen. b. Place the mouse in the imaging chamber of the NIR-II fluorescence microscope. c. Set the excitation laser to 808 nm with a power density of 100 mW/cm². d. Configure the detection path with a 1500 nm long-pass filter and an InGaAs camera cooled to -80°C.
• Image Acquisition: Acquire time-series images at 0, 1, 5, 10, 30, 60, and 120 minutes post-injection. Use an exposure time of 100-300 ms. Maintain anesthesia and body temperature (37°C) throughout.
• Data Analysis: Use Fiji/ImageJ to calculate tumor-to-background ratio (TBR), quantify vessel diameter, and measure perfusion kinetics. Generate 3D vascular maps via maximum intensity projection (MIP).

Protocol 4.2: multiplexed imaging of Tumor Microenvironment Components

Objective: To simultaneously visualize tumor vessels (NIR-IIa) and pH-sensitive immune cell activity (NIR-IIb). Procedure:

• Dual-Probe Cocktail: Prepare a mixture of Ag2S quantum dots (emission 1200 nm, for vasculature) and a pH-sensitive lanthanide-based nanoparticle (emission 1550 nm, activated in acidic tumor niches).
• Spectral Unmixing Imaging: a. Inject the probe cocktail intravenously. b. Acquire images using a spectral detection system (e.g., discrete filters at 1250 nm and 1550 nm, or a spectrometer-coupled camera). c. Apply linear unmixing algorithms to separate the two emission signals, assigning a distinct false color to each probe (e.g., green for vasculature, red for acidic regions).

Diagram Title: NIR-II Imaging Workflow for Tumor Microenvironment (TME) Analysis

The Scientist's Toolkit: Key Research Reagent Solutions

Table 2: Essential Materials for NIR-II Tumor Microenvironment Imaging

Item	Category	Example Product/Type	Function in Experiment
NIR-II Fluorophore	Probe	CH-105T organic dye; Ag2S Quantum Dots; Er³+-doped nanoparticles	Acts as the contrast agent, emitting light in the NIR-II window upon excitation.
NIR Laser	Equipment	808 nm or 980 nm diode laser	Provides excitation photons for the fluorophore. 808 nm is common for many probes.
InGaAs Camera	Equipment	Two-dimensional cooled InGaAs array (Princeton Instruments, Nüvü)	Detects low-intensity NIR-II emission with high sensitivity and low noise.
Long-pass Filters	Optical Component	1000 nm, 1200 nm, 1500 nm long-pass filters	Blocks excitation laser light and allows only NIR-II emission to reach the detector.
Spectral Separator	Optical Component	Acousto-optic tunable filter (AOTF) or filter wheel	Enables multiplexed imaging by isolating specific emission bands for spectral unmixing.
Animal Model	Biological	Athymic nude mouse with xenograft (e.g., 4T1, U87-MG)	Provides an in vivo model of a tumor with a human-like microenvironment.
Image Analysis Software	Software	Fiji/ImageJ with custom macros; Living Image; MATLAB	Used for quantification of intensity, kinetics, 3D reconstruction, and colocalization analysis.
Anesthesia System	Equipment	Isoflurane vaporizer with induction chamber	Maintains the animal in a stable, immobile state for prolonged imaging sessions.

Within the context of advancing NIR-II (1000-1700 nm) fluorescence imaging for tumor microenvironment (TME) research, the core advantages of this modality are transformative. The NIR-II window offers unmatched spatial resolution due to reduced photon scattering in biological tissues, enabling deep-tissue, high-fidelity visualization. Critically, it minimizes autofluorescence from biomolecules like flavins and porphyrins, which plague the visible and NIR-I regions, resulting in a dramatically improved signal-to-background ratio (SBR). These intrinsic advantages make NIR-II imaging indispensable for probing dynamic processes in the TME, including angiogenesis, immune cell infiltration, and drug delivery kinetics.

Quantitative Advantages of NIR-II Imaging

Table 1: Comparative Performance Metrics of Fluorescence Imaging Windows

Parameter	Visible (400-700 nm)	NIR-I (700-900 nm)	NIR-II (1000-1700 nm)	Measurement Context
Tissue Scattering Coefficient	High (~100 cm⁻¹ at 500 nm)	Moderate (~40 cm⁻¹ at 800 nm)	Low (~10 cm⁻¹ at 1300 nm)	In vivo brain tissue
Typical Autofluorescence Background	Very High	High	Negligible/Low	In vivo mouse model, tumor site
Achievable Spatial Resolution	~1-3 mm at 1 mm depth	~100-200 µm at 2 mm depth	~20-50 µm at 3 mm depth	Subcutaneous tumor vasculature imaging
Maximum Imaging Depth	< 1 mm	2-3 mm	5-8 mm	Through intact skull/brain tissue
Signal-to-Background Ratio (SBR)	Low (1-3)	Moderate (5-10)	High (20-100+)	Vessel-to-tissue contrast in angiography

Table 2: Performance of Representative NIR-II Probes in TME Imaging

Probe Type	Emission Max (nm)	Quantum Yield (%)	Application in TME	Reported SBR	Key Advantage
Ag₂S Quantum Dots	1200-1300	5-15	Angiogenesis, lymph node mapping	~45 at 4 mm depth	High brightness, good biocompatibility
Lanthanide-Doped NPs (Er³⁺)	1525	~1-5	Metastatic sentinel lymph node imaging	>50 at 5 mm depth	Ultra-narrow emission, ideal for spectral unmixing
Organic Dye (CH1055)	1055	0.3-0.5	Tumor targeting, pharmacokinetics	~12 at 3 mm depth	Rapid renal clearance, potential for clinical translation
Single-Walled Carbon Nanotubes	1300-1400	<1	Protease activity sensing	~30 at 2 mm depth	Multiplexed sensing, high photostability
D-A-D Organic Dye (IR-FE)	1060	2.1	Tumor metabolic imaging	>15 at 3 mm depth	High molar extinction, tailorable chemistry

Application Notes

High-Resolution Dynamic Imaging of Tumor Angiogenesis

Objective: Visualize the chaotic and leaky vasculature of a tumor with capillary-level detail to assess anti-angiogenic therapy efficacy. Rationale: Reduced scattering in the NIR-II window allows for resolving sub-10µm capillaries at depths exceeding 1mm, which is impossible in NIR-I. Minimal autofluorescence provides a dark background, making perfused vessels starkly clear. Protocol: See Section A.

Quantifying Immune Cell Trafficking in the TME

Objective: Track the infiltration of NIR-II-labeled immune cells (e.g., CAR-T cells, macrophages) into solid tumors in real time. Rationale: The high SBR enables distinguishing labeled cells from heterogeneous tissue autofluorescence. Deep penetration allows observation of cell movement in deep-seated or orthotopic tumors. Protocol: See Section B.

Sensitive Detection of Targeted Molecular Events

Objective: Image specific protease activity (e.g., Cathepsin B) or pH changes within the TME using activatable NIR-II probes. Rationale: The low background autofluorescence in NIR-II makes small changes in activation ratio detectable, significantly improving the sensitivity of molecular sensing in vivo.

Experimental Protocols

Protocol A: High-Resolution NIR-II Angiography for Tumor Vasculature Mapping

Materials: NIR-II fluorophore (e.g., IRDye 1200CW, 100 nmol/kg), NIR-II imaging system with 1064 nm excitation laser and InGaAs camera, anesthetized tumor-bearing mouse, heating pad. Procedure:

• Tail Vein Injection: Warm the mouse tail in warm water (~37°C) for 1-2 minutes to dilate the vein. Inject the NIR-II probe via tail vein in a total volume of 100-150 µL of PBS.
• Animal Positioning: Place the anesthetized mouse in the imaging chamber, maintaining body temperature at 37°C. Position the tumor region of interest in the focal plane.
• Image Acquisition:
  • Set laser power to 100 mW/cm² (ensure it is within safety limits).
  • Set camera acquisition parameters: exposure time = 20-100 ms, binning = 1 (for high resolution), frame rate = 5-10 Hz for dynamics.
  • Acquire images continuously for 1-2 minutes post-injection to capture the bolus passage, then every minute for 20 minutes.
  • Use appropriate long-pass filters (e.g., LP1250 nm) to collect pure NIR-II signal.
• Data Analysis: Use software (e.g., ImageJ, MATLAB) to generate time-intensity curves, calculate vessel diameter, and perform 3D vascular reconstruction from Z-stacks.

Protocol B: Longitudinal Tracking of NIR-II-Labeled Immune Cells in the TME

Materials: Primary immune cells (e.g., T cells), NIR-II cell labeling kit (e.g., membrane-intercalating dye), cell culture reagents, fluorescence-activated cell sorter (FACS), orthotopic tumor mouse model, NIR-II imager. Procedure:

• Cell Labeling:
  • Isolate and activate target immune cells ex vivo.
  • Resuspend cells at 1-5 x 10⁶ cells/mL in serum-free medium.
  • Add NIR-II labeling reagent at manufacturer-recommended concentration (e.g., 1-10 µM).
  • Incubate for 20-30 minutes at 37°C.
  • Wash cells 3x with complete medium to remove excess dye. Confirm labeling efficiency and viability via FACS.
• Cell Administration: Inject 1-5 x 10⁶ labeled cells intravenously or intratumorally into the tumor-bearing mouse.
• Longitudinal Imaging:
  • Anesthetize and image the mouse at predetermined time points (e.g., 1h, 24h, 72h, 1 week post-injection).
  • Use consistent imaging parameters (laser power, exposure time, focus) across all sessions.
  • Acquire both NIR-II fluorescence and white-light reference images.
• Quantification: Define regions of interest (ROI) for the tumor and a contralateral control tissue. Plot total radiant efficiency ([fluorescence intensity]/[laser power]) in the tumor ROI over time to quantify cell recruitment kinetics.

Diagrams

Title: NIR-II In Vivo Imaging Workflow

Title: Core Advantages Logic: NIR-II vs NIR-I/VIS

The Scientist's Toolkit

Table 3: Essential Research Reagent Solutions for NIR-II TME Imaging

Item	Category	Function & Rationale
NIR-II Fluorophores (e.g., IR-1061, CH1055 derivatives)	Imaging Probe	The core agent that emits in the NIR-II window. Selected based on brightness, stability, targeting moiety, and clearance profile.
PEGylation Reagents (e.g., mPEG-NHS)	Probe Modifier	Conjugated to probes to improve hydrophilicity, extend blood circulation half-life, and reduce non-specific uptake.
Targeting Ligands (e.g., cRGD, Anti-VEGFR Antibody)	Probe Modifier	Conjugated to NIR-II probes to achieve active targeting of specific TME components like angiogenic vessels or immune checkpoints.
Matrix Metalloproteinase (MMP) Substrate Peptides	Activatable Probe Component	Integrated into probe design to create "smart" probes that fluoresce only upon cleavage by specific TME-associated enzymes.
Dialysis Membranes (MWCO 3.5-14 kDa)	Purification Tool	Essential for removing unreacted dyes and small molecules during probe synthesis and conjugation steps.
Size Exclusion Chromatography Columns	Purification Tool	Used to separate and purify nanoparticulate NIR-II probes (e.g., quantum dots, nanotubes) from aggregates or byproducts.
Anesthesia System (Isoflurane/Oxygen)	In Vivo Tool	Provides stable and reversible anesthesia for longitudinal imaging sessions, ensuring animal welfare and motion-free images.
Liquid Nitrogen	Storage	Required for long-term storage of sensitive biological samples (cells, antibodies) and some probe precursors.

Within the broader thesis on developing next-generation NIR-II fluorescent probes for tumor microenvironment (TME) research, spectral selection is paramount. Moving beyond the conventional NIR-II window (900-1700 nm), the sub-windows NIR-IIa (1300-1400 nm) and NIR-IIb (1500-1700 nm) offer reduced photon scattering and virtually autofluorescence-free imaging. This application note details the quantitative advantages of these sub-bands and provides standardized protocols for their application in visualizing deep-tissue tumor architecture, vascular dynamics, and molecular targets.

Quantitative Comparison of NIR Sub-Windows

Table 1: Photophysical Properties of NIR Imaging Windows

Imaging Window	Wavelength Range (nm)	Tissue Scattering Coefficient (Relative to NIR-I)	Autofluorescence Level	Approximate Penetration Depth in Tissue (mm)	Typical Resolution (µm)
NIR-I / NIR-II	700-900	1.0 (Reference)	High	1-3	~1000
NIR-II	900-1700	~0.25	Low	3-8	~30
NIR-IIa	1300-1400	~0.1	Negligible	5-10	~15-25
NIR-IIb	1500-1700	~0.05	Undetectable	7-12+	~10-20

Table 2: Suitability for TME Research Applications

Application	Preferred Window	Rationale
Deep-tumor 3D morphology	NIR-IIb	Maximum penetration and scattering reduction for whole-tumor visualization.
High-speed vascular dynamics (angiogenesis)	NIR-IIa	Excellent balance of reduced scattering and high detector sensitivity for frame rate > 50 fps.
Multiplexed imaging of biomarkers	NIR-IIa & NIR-IIb	Enables spectral separation of multiple probes with minimal crosstalk.
Sentinel lymph node mapping	NIR-IIb	Lowest background for precise, high-contrast delineation of lymphatic structures.
Intraoperative guidance	NIR-IIa	Superior resolution for identifying tumor margins in real-time.

Research Reagent Solutions Toolkit

Table 3: Essential Materials for NIR-IIa/b TME Imaging

Item	Function & Application
NIR-IIb-emitting Quantum Dots (e.g., PbS/CdS QDs, ~1550 nm emission)	High-brightness, photostable probes for deep-tumor vasculature mapping and long-term tracking.
NIR-IIa Small-Molecule Dye (e.g., CH-4T, emission ~1300 nm)	Rapid clearance, ideal for high-resolution angiography and metabolic targeting in the TME.
Targeted Lanthanide Nanoparticles (Er³⁺, emission ~1550 nm)	For multiplexed imaging and sensing of TME parameters (pH, hypoxia) via narrow, non-bleaching emission bands.
InGaAs Camera with 2D Array (Detection up to 1700 nm)	Essential detector for NIR-IIb imaging. Requires cooling to -80°C for low-noise performance.
Dichroic Beamsplitters & Long-pass Filters (Cut-on: 1300 nm, 1500 nm)	Optical components to isolate NIR-IIa and NIR-IIb signals from excitation light and shorter wavelengths.
Dispersion Compensation Unit	Corrects for chromatic aberration in optical path when imaging across broad NIR-II spectrum.
Sterile PBS for In Vivo Administration	Vehicle for probe dilution and control injections.
Isoflurane/Oxygen Vaporizer System	For safe and stable anesthesia during longitudinal in vivo imaging sessions.
Matrigel or similar Basement Membrane Matrix	For orthotopic or subcutaneous tumor cell implantation to model the TME.

Experimental Protocols

Protocol 1: High-Resolution Vasculature Imaging in Orthotopic Tumor Model

Objective: To visualize tumor-associated angiogenesis with ultimate clarity using NIR-IIb emission. Probe: PEGylated PbS/CdS Quantum Dots (λem = 1550 nm). Model: Orthotopic breast cancer (4T1) in BALB/c mouse.

Procedure:

• Tumor Implantation: Inject 1x10⁶ 4T1 cells in 20 µL PBS:Matrigel (1:1) into the mammary fat pad.
• Probe Administration: At tumor volume ~150 mm³, administer QDs (200 pmol in 100 µL PBS) via tail vein injection.
• Image Acquisition (24h post-injection):
  • Anesthetize mouse with 2% isoflurane.
  • Place animal in prone position on warming stage in imaging system.
  • Excitation: 808 nm laser at 100 mW/cm².
  • Detection: Use 1500 nm long-pass filter and InGaAs camera.
  • Acquire dynamic images for 5 min (30 fps) to capture vascular flow.
  • Acquire high-sensitivity static image (integration time: 300 ms) for 3D tomography.
• Image Analysis: Calculate tumor-to-background ratio (TBR), vessel density, and diameter using AngioTool or similar software.

Protocol 2: Multiplexed Imaging of Tumor Margins with NIR-IIa & IIb Probes

Objective: To simultaneously delineate tumor vasculature and a targeted biomarker for margin assessment. Probes: NIR-IIa: anti-EGFR-CH-4T (λem = 1300 nm). NIR-IIb: Integrin-targeted Er³⁺-nanoparticles (λem = 1550 nm). Model: Subcutaneous glioblastoma (U87MG) in nude mouse.

Procedure:

• Probe Cocktail Preparation: Mix the two probes (100 pmol each) in 150 µL sterile PBS. Incubate at 4°C for 10 min.
• Administration: Inject cocktail via tail vein.
• Dual-Channel Image Acquisition (48h for targeted probes):
  • Anesthetize and position mouse.
  • Excitation: Use 980 nm laser (excites both probes).
  • Detection Channel 1 (NIR-IIa): Use 1300/100 nm bandpass filter.
  • Detection Channel 2 (NIR-IIb): Use 1550/100 nm bandpass filter.
  • Acquire coregistered images in both channels sequentially.
• Analysis: Generate an overlay image. Use spectral unmixing if necessary. Quantify signal overlap (Pearson's coefficient) at the infiltrative tumor boundary vs. healthy tissue.

Visualizations

NIR Spectrum Breakdown to Ultimate Clarity

Protocol Workflow for NIR-IIa/b TME Imaging

Application Notes

Within the context of a thesis on NIR-II (1000-1700 nm) probes for visualizing the tumor microenvironment (TME), each class of probe offers distinct advantages and challenges for researchers studying tumor biology, angiogenesis, drug delivery, and therapeutic response.

Organic Fluorophores are small molecules or conjugated polymers engineered for NIR-II emission. Their primary application lies in rapid, high-resolution dynamic imaging of vascular structures and tumor margins due to their fast pharmacokinetics. They are ideal for real-time intraoperative guidance and pharmacokinetic studies but often suffer from moderate quantum yield and photobleaching.

Quantum Dots (QDs), particularly those based on Ag2S, PbS, or InAs, provide bright, stable, and tunable NIR-II fluorescence. They are exceptionally suited for long-term, multiplexed imaging of specific biomarkers within the TME (e.g., targeting endothelial cells or tumor-associated macrophages). Their potential cytotoxicity and long-term retention, however, require careful surface functionalization for biological applications.

Single-Walled Carbon Nanotubes (SWCNTs) exhibit intrinsic NIR-II photoluminescence with exceptional photostability and deep tissue penetration. They are powerful as high-sensitivity, multiplexed sensors for tracking subtle changes in the TME, such as pH, reactive oxygen species, or enzyme activity. Their application is often limited by complex biocompatibility engineering and potential batch-to-batch variability.

Lanthanide-Doped Nanoparticles (LDNPs), such as NaYF4:Nd3+, Yb3+, Er3+, offer long-lived luminescence (microseconds to milliseconds), enabling time-gated imaging to completely eliminate short-lived autofluorescence. This makes them unparalleled for achieving ultra-high signal-to-background ratio imaging of deep-seated tumors and for advanced modalities like luminescence lifetime imaging (LLI) to sense microenvironmental parameters like temperature or oxygen pressure.

Quantitative Comparison of NIR-II Probe Classes

Table 1: Key Characteristics of NIR-II Probe Classes for TME Imaging

Probe Class	Emission Range (nm)	Quantum Yield	Excitation Source	Key Advantage for TME	Primary Limitation
Organic Fluorophores	900-1300	0.1-5%	~800 nm NIR laser	Fast clearance, real-time angiography	Moderate brightness, photobleaching
Quantum Dots	1000-2000	5-30%	~808 nm NIR laser	High brightness, multiplexing	Potential heavy metal toxicity
Carbon Nanotubes	1000-1600	0.1-1%	~808 nm NIR laser	Extreme photostability, sensing	Complex functionalization, polydispersity
Lanthanide Nanoparticles	1000-1600	0.1-10%	~808 nm or 980 nm	No autofluorescence (time-gated), LLI	Requires pulsed laser, lower peak brightness

Experimental Protocols

Protocol 1: Conjugation of RGD Peptide to Ag2S Quantum Dots for αvβ3 Integrin Targeting in Tumors

This protocol details the functionalization of NIR-II QDs for targeting angiogenic vasculature in the TME.

Materials:

• Ag2S QDs (NIR-II emission at 1200 nm) in organic solvent
• DSPE-PEG(2000)-COOH phospholipid
• RGDfK peptide (cyclo(Arg-Gly-Asp-D-Phe-Lys))
• NHS/EDC coupling reagents
• Chloroform, DMSO, PBS (pH 7.4)

Procedure:

• Phase Transfer: Mix 1 mL of Ag2S QDs in chloroform with 5 mg of DSPE-PEG-COOH. Evaporate chloroform under nitrogen to form a thin film. Hydrate the film with 2 mL of PBS (pH 7.4) and sonicate for 30 min to form PEGylated QDs in aqueous solution.
• Peptide Activation: Dissolve 2 mg of RGDfK peptide in 1 mL of DMSO. Add a 10-fold molar excess of EDC and NHS to the peptide solution. React for 30 min at room temperature with gentle stirring.
• Conjugation: Add the activated peptide solution dropwise to the PEGylated QD solution. Adjust the pH to 8.0-8.5 with sodium borate buffer. React overnight at 4°C with continuous stirring.
• Purification: Purify the RGD-QD conjugates via size-exclusion chromatography (Sephadex G-25) equilibrated with PBS. Collect the first colored band. Filter sterilize (0.22 µm).
• Validation: Confirm conjugation via UV-Vis-NIR spectroscopy (characteristic peaks of QD and peptide) and test targeting efficacy on αvβ3-positive U87MG cells in vitro.

Protocol 2: Time-Gated NIR-II Imaging with Lanthanide Nanoparticles for Deep-Tumor Imaging

This protocol outlines the use of pulsed laser excitation to eliminate autofluorescence when imaging the TME with LnNPs.

Materials:

• NaYF4: 20% Nd, 2% Yb, 0.5% Er nanoparticles (core-shell design)
• 980 nm pulsed laser diode (pulse width: 100 µs, repetition rate: 100 Hz)
• NIR-II InGaAs camera (cooled to -80°C)
• Time-gated delay generator
• Mouse model with subcutaneous tumor

Procedure:

• Probe Administration: Inject 200 µL of LnNP suspension (2 mg/mL in PBS) intravenously via the tail vein.
• Imaging Setup: Anesthetize the mouse and place it on a heated stage. Position the 980 nm pulsed laser for epi-illumination. Synchronize the laser pulse trigger with the camera exposure via a delay generator.
• Time-Gated Acquisition:
  • Set camera exposure time to 10 ms.
  • Set the delay generator to open the camera shutter after the laser pulse has ended (e.g., a 500 µs delay after a 100 µs laser pulse).
  • Acquire a sequence of images (e.g., 100 frames). The short-lived tissue autofluorescence (ns scale) decays completely before the camera gate opens, while the long-lived LnNP luminescence (µs-ms scale) is captured.
• Data Processing: Sum or average the acquired frames. Apply background subtraction and generate signal-to-background ratio maps. Compare with continuous-wave (CW) images taken without time-gating to quantify improvement.

Diagrams

Title: NIR-II Probe Selection Guide for TME Studies

Title: Workflow for Targeted NIR-II Probe Delivery & Imaging

The Scientist's Toolkit: Research Reagent Solutions

Table 2: Essential Materials for NIR-II TME Imaging Experiments

Item	Function & Application	Example Product/Catalog
NIR-II Organic Dye (e.g., CH1055)	Small-molecule fluorophore for fast, high-resolution vascular imaging.	Lumiprobe, #FC-1060
Ag2S Quantum Dots (PEGylated)	High-quantum-yield probes for long-term, targeted biomarker tracking.	PlasmaChem, #aqsln-1000
Functionalized SWCNTs	Photostable nanoprobes for sensing pH, ROS, or enzymes in the TME.	NanoIntegris, #IsoSol-S100
NaYF4:Nd/Yb/Er Nanoparticles	Lanthanide probes for time-gated, autofluorescence-free deep imaging.	Sigma-Aldrich, #900611
Anti-CD31 Antibody, Alexa Fluor 790	Vascular endothelial staining for correlative NIR-I/NIR-II imaging.	BioLegend, #102428
Matrigel Matrix	For creating 3D tumor spheroid models to mimic the TME in vitro.	Corning, #356231
808 nm & 980 nm Laser Diodes	Continuous-wave excitation sources for NIR-II probes.	Thorlabs, #L808P1W
Cooled InGaAs NIR-II Camera	High-sensitivity detection of NIR-II photons (900-1700 nm).	Princeton Instruments, #NIRvana-640
Time-Gated Delay Generator	Enables pulsed excitation & gated detection for LnNP imaging.	Stanford Research Systems, #DG645
IVIS Spectrum CT Imaging System	Integrated platform for multi-modal (NIR-II + CT) in vivo imaging.	PerkinElmer, #CLS136337

From Lab to Living System: Practical Strategies for NIR-II Probe Design and TME Targeting

Synthetic Strategies for High-Performance NIR-II Organic Dyes (D-A-D, D-π-A Structures)

This document provides detailed application notes and experimental protocols for the synthesis of high-performance NIR-II organic dyes, specifically focusing on Donor-Acceptor-Donor (D-A-D) and Donor-π-Acceptor (D-π-A) molecular architectures. This work is situated within a broader thesis research program aimed at developing advanced fluorescent probes for the high-resolution visualization of the tumor microenvironment (TME). Precise imaging of dynamic TME parameters—such as hypoxia, pH, enzyme activity, and vascular permeability—requires dyes with excellent photophysical properties, including bright NIR-II emission, high photostability, and good biocompatibility. The synthetic strategies outlined here are foundational for creating the molecular tools necessary for this research.

---

Core Design Principles & Quantitative Data

The photophysical properties of NIR-II dyes are directly governed by the strength of the donor (D) and acceptor (A) units, the length and planarity of the π-conjugation bridge, and the overall molecular packing.

Table 1: Common Building Blocks for NIR-II Dye Synthesis

Component	Example Structures	Key Function & Property
Strong Donors (D)	Triphenylamine, Phenothiazine, Cyclopentadithiophene, Diketopyrrolopyrrole (as donor)	Increase electron density, raise HOMO level, red-shift emission. Provide molecular asymmetry to inhibit crystallization.
Acceptors (A)	Benzobisthiadiazole (BBTD), Thiadiazoloquinoxaline (TQ), Difluorobenzothiadiazole (ffBT), Isoindigo, Aza-BODIPY	Strong electron-withdrawing capability, lower LUMO level, narrow bandgap. Often core fluorophore for NIR-II emission.
π-Spacers	Thiophene, Vinylene (C=C), Ethynylene (C≡C), Furan, Selenophene	Extend conjugation, modulate planarity and rotational freedom, fine-tune solubility and emission wavelength.
Solubilizing Groups	Branched alkyl chains (e.g., 2-ethylhexyl, 2-butyloctyl), Polyethylene glycol (PEG), Sulfonate groups	Ensure solubility in organic solvents or aqueous media, prevent aggregation-caused quenching (ACQ), enable nanoparticle formulation.

Table 2: Representative D-A-D and D-π-A Dyes & Their Photophysical Properties

Data sourced from recent literature (2023-2024).

Dye Structure	λ_abs (nm)	λ_em (nm)	Quantum Yield (Φ)	Brightness (ε×Φ)	Application Focus in TME
D-A-D: CPT-BBTD-CPT	808	1025	1.2% in PBS	~1,800 M⁻¹cm⁻¹	Vascular imaging, tumor delineation
D-π-A: TPA-Th-ffBT	780	980	5.6% in DCM	~28,000 M⁻¹cm⁻¹	Protease-activated probe design
D-A-D: DPTQ-ET	860	1100	0.8% in Aqueous NPs	~9,600 M⁻¹cm⁻¹	Lymph node mapping, passive targeting
D-π-A: PEGylated CH1055 derivative	755	1055	2.3% in Serum	~11,500 M⁻¹cm⁻¹	Antibody-dye conjugate for targeted imaging

---

Detailed Synthetic Protocols

Protocol 2.1: General Suzuki-Miyaura Cross-Coupling for D-π-A Dye Synthesis

This is a quintessential reaction for constructing conjugated systems between aromatic donors and acceptors.

Title: Synthesis of TPA-Th-ffBT Model Dye.

Materials:

• Reagents: Tributyl(4-(diphenylamino)phenyl)stannane (Donor, 1.1 eq.), 4,7-dibromo-5,6-difluorobenzo[c][1,2,5]thiadiazole (ffBT Acceptor, 1.0 eq.), Tetrakis(triphenylphosphine)palladium(0) (Pd(PPh₃)₄, 3 mol%), Dry Toluene, 2M Aqueous K₂CO₃.
• Equipment: Schlenk flask, magnetic stirrer, reflux condenser, argon/vacuum line, heating mantle, TLC plates, silica gel, rotary evaporator.

Procedure:

• Reaction Setup: In an argon-purged Schlenk flask, combine the ffBT acceptor (100 mg, 0.28 mmol), Pd(PPh₃)₄ (10 mg, 8.7 µmol), and a stir bar.
• Solvent Addition: Add degassed toluene (15 mL) via syringe.
• Donor Addition: Add the tributylstannane donor (198 mg, 0.31 mmol) via syringe.
• Base Addition: Carefully add degassed 2M K₂CO₃ solution (5 mL).
• Reaction: Heat the mixture to 110°C under argon and reflux for 18-24 hours. Monitor by TLC (eluent: Hexanes/DCM 1:1).
• Work-up: Cool to room temperature. Dilute with DCM (50 mL) and wash with water (3 x 30 mL) and brine (1 x 30 mL). Dry the organic layer over anhydrous Na₂SO₄.
• Purification: Concentrate in vacuo. Purify the crude product by silica gel column chromatography (gradient: hexanes to hexanes/DCM 1:1) to afford a dark green solid. Characterize by ¹H/¹³C NMR and HRMS.

Protocol 2.2: Knoevenagel Condensation for A-D-A Type Dyes (Variant of D-A-D)

A key reaction for constructing dyes with strong electron-withdrawing terminal groups (e.g., dicyanovinyl, rhodanine).

Title: Condensation to Form Dicyanovinyl-Terminated Acceptor Core.

Materials:

• Reagents: Benzobisthiadiazole (BBTD) dialdehyde (1.0 eq.), Malononitrile (2.5 eq.), Anhydrous Chloroform, Piperidine (catalyst, 0.1 eq.), Glacial Acetic Acid (co-catalyst), Molecular Sieves (4Å).
• Equipment: Round-bottom flask, reflux condenser, argon line, oil bath.

Procedure:

• In a dry flask, dissolve the BBTD dialdehyde (50 mg, 0.1 mmol) and malononitrile (33 mg, 0.5 mmol) in anhydrous chloroform (10 mL).
• Add a catalytic amount of piperidine (2 µL) and glacial acetic acid (5 µL). Add a spoonful of activated 4Å molecular sieves.
• Reflux the reaction mixture under argon at 70°C for 6-8 hours until TLC indicates complete consumption of the starting dialdehyde.
• Cool the mixture and filter to remove molecular sieves.
• Concentrate under reduced pressure. Precipitate the product by adding the concentrate to rapidly stirring methanol (50 mL). Filter the resulting dark precipitate and wash with cold methanol. Further purify by Soxhlet extraction with methanol and chloroform. The dye is obtained from the chloroform fraction.

---

Formulation Protocol for Aqueous Biological Application

Protocol 3.1: DSPE-mPEG Encapsulation for Nanoparticle (NP) Formation

Most high-performance organic dyes are hydrophobic. This protocol describes their encapsulation into biocompatible, dispersible nanoparticles.

Title: Preparation of NIR-II Dye-Loaded PEGylated Nanoparticles.

Materials: Hydrophobic NIR-II dye (e.g., DPTQ-ET), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (DSPE-mPEG2000), Tetrahydrofuran (THF, HPLC grade), Phosphate Buffered Saline (PBS, 1x, pH 7.4), Dialysis tubing (MWCO 3.5 kDa).

Procedure:

• Stock Solutions: Dissolve dye (0.5 mg) and DSPE-mPEG2000 (5 mg) separately in THF (1 mL each).
• Mixing: Rapidly inject the combined THF solutions (total 2 mL) into vigorously stirred PBS (10 mL) using a syringe pump (rate: 1 mL/min). A cloudy suspension will form immediately.
• Stirring: Continue stirring the suspension at room temperature for 2 hours to allow THF evaporation and nanoparticle assembly.
• Dialysis: Transfer the suspension to dialysis tubing and dialyze against 2 L of PBS for 24 hours, changing the PBS buffer every 6-8 hours to remove residual THF and free dye.
• Characterization: Filter the final solution through a 0.22 µm filter. Determine nanoparticle size and PDI by dynamic light scattering (DLS). Measure dye concentration via UV-Vis-NIR absorption spectroscopy using its molar extinction coefficient.

---

The Scientist's Toolkit: Research Reagent Solutions

Table 3: Essential Materials for NIR-II Dye Development

Reagent/Material	Supplier Examples	Function in Research
Strong Acceptor Cores (BBTD, TQ, ffBT)	TCI, Sigma-Aldrich, Specific Chinese suppliers (e.g., Bide Pharmatech)	Core building block defining emission wavelength and photostability.
Palladium Catalysts (Pd₂(dba)₃, Pd(PPh₃)₄, SPhos Pd G3)	Sigma-Aldrich, Strem Chemicals, Combi-Blocks	Catalyze key C-C bond formations (Suzuki, Stille, Buchwald-Hartwig).
Anhydrous, Degassed Solvents (THF, Toluene, DMF)	Sigma-Aldrich (SealSure), Acros Organics	Ensure successful organometallic coupling reactions.
DSPE-mPEG2000 (and other PEG-lipids)	Avanti Polar Lipids, NOF America, CordenPharma	Form stable, biocompatible, long-circulating nanoparticles for in vivo studies.
Size Exclusion Chromatography (SEC) Columns	Bio-Rad, Cytiva	Purify dye-biomolecule conjugates (e.g., antibodies, peptides).
NIR-II Calibration Standards (e.g., IR-26)	Luminescence Technology Corp.	Essential for accurate measurement of NIR-II quantum yields in different solvents.

---

Visualizations: Pathways & Workflows

Title: Molecular Design Logic for D-A-D NIR-II Dyes

Title: NIR-II Dye Development Workflow

Title: NIR-II Probe Activation in Tumor Microenvironment

Within the context of developing advanced NIR-II (1000-1700 nm) optical probes for visualizing the tumor microenvironment, the precise engineering of inorganic nanoparticles is paramount. Quantum Dots (QDs) and Rare-Earth Doped Nanoparticles (RENPs) offer distinct advantages, including size-tunable emission, high photostability, and deep-tissue penetration. This document provides detailed application notes and protocols for synthesizing and functionalizing these probes, with the goal of optimizing their performance for in vivo TME research, including vascular imaging, lymphatic tracking, and sensing of pathological parameters.

Comparative Properties: QDs vs. RENPs for NIR-II Imaging

Table 1: Key Characteristics of NIR-II Emitting Inorganic Probes

Property	Ag₂S / Ag₂Se Quantum Dots	PbS/CdHgTe Quantum Dots	NaYF₄:Yb,Er/Ce (RENPs)	NaYF₄:Yb,Tm (RENPs)
Core Composition	Silver chalcogenides	Lead/Cadmium chalcogenides	Lanthanide-doped sodium yttrium fluoride	Lanthanide-doped sodium yttrium fluoride
Primary Emission Range	1000-1300 nm	1200-1600 nm	~1550 nm (Er³⁺)	800 nm, ~1200-1500 nm (Tm³⁺)
Excitation Wavelength	~808 nm	~808 nm	~980 nm	~980 nm
Quantum Yield (NIR-II)	5-15% (in solution)	10-30% (in solution)	5-20% (core-shell)	0.5-5% (core-shell)
Size Range (Core)	2-5 nm	3-7 nm	20-50 nm (core)	20-50 nm (core)
Key Engineering Handle	Precursor ratio, temperature	Shell growth (CdS/ZnS)	Shell architecture (inert/active)	Shell architecture, sensitizer density
Primary Advantage	Biocompatible elements, small size	High brightness, tunable IR emission	Sharp bands, long lifetime, low background	Multi-wavelength emission (NIR-I & II)
Primary Challenge	Moderate QY, oxidation	Potential heavy metal toxicity	Low absorption cross-section, water quenching	Low QY at NIR-II wavelengths

Protocols for Probe Synthesis and Engineering

Protocol 3.1: Hot-Injection Synthesis of Ag₂S Quantum Dots (NIR-II, ~1050 nm)

Objective: To synthesize small, water-dispersible Ag₂S QDs with emission in the NIR-IIb window. Research Reagent Solutions:

• Silver Acetate (AgOAc): Silver precursor.
• Sulfur (S) in Oleylamine (OLA): Sulfur source and reducing solvent.
• 1-Dodecanethiol (DDT): Ligand for surface stabilization and growth control.
• Octadecene (ODE): Non-coordinating solvent.
• Poly(maleic anhydride-alt-1-octadecene) (PMAO): Amphiphilic polymer for phase transfer to water.

Methodology:

• In a three-neck flask, mix 0.1 mmol AgOAc, 2 mL ODE, and 2 mL OLA. Degas under vacuum at 100°C for 20 min.
• Under N₂ flow, heat to 120°C. Rapidly inject 0.05 mmol S dissolved in 1 mL OLA and 0.5 mL DDT.
• React for 10-20 minutes at 120°C, monitoring emission with a NIR spectrometer. Quench by ice bath.
• Purify by precipitation with ethanol/acetone, centrifuge (12,000 rpm, 10 min), and redisperse in chloroform.
• Aqueous Phase Transfer: Dissolve 10 mg PMAO in chloroform. Mix with purified QDs. Rotate-evaporate to form a thin film. Hydrate with PBS or water (pH 8-9) and sonicate to obtain clear aqueous dispersion. Filter through a 0.22 µm filter.

Protocol 3.2: Thermal Decomposition Synthesis of Core-Shell NaYF₄:Yb,Er@NaYF₄ RENPs

Objective: To synthesize bright, core-shell RENPs with enhanced NIR-II emission at 1550 nm via suppressed surface quenching. Research Reagent Solutions:

• Rare-Earth Acetates (RE(OAc)₃, RE=Y, Yb, Er): Precursors for host and dopant ions.
• Oleic Acid (OA) & Octadecene (ODE): Coordinating ligand and solvent system.
• Ammonium Fluoride (NH₄F) & Sodium Hydroxide (NaOH): Fluoride and sodium sources.
• Citric Acid: Ligand for hydrophilic coating.

Methodology:

• Core Synthesis: In a 100 mL flask, mix Y(OAc)₃ (0.78 mmol), Yb(OAc)₃ (0.20 mmol), Er(OAc)₃ (0.02 mmol) with 6 mL OA and 15 mL ODE. Heat to 150°C under N₂ for 30 min to form a clear solution, then cool to 50°C.
• Add a methanol solution containing NH₄F (4 mmol) and NaOH (2.5 mmol). Stir for 30 min.
• Slowly remove methanol by heating to 100°C, then heat to 300°C under N₂ and maintain for 60 min. Cool to room temperature. Precipitate with ethanol, centrifuge, and redisperse in cyclohexane.
• Shell Growth: Repeat step 1 using only Y(OAc)₃ for inert shell precursors. At 50°C, add the purified core nanoparticles in cyclohexane. Follow steps 2 and 3, but increase reaction time at 300°C to 90 min for uniform shell growth.
• Hydrophilic Coating: Add citric acid (50 mg) in water to the core-shell nanoparticles in cyclohexane. Vigorously stir for 24h at 70°C. The nanoparticles transfer to the aqueous phase. Collect and filter (0.22 µm).

Key Application: Probing Tumor Microenvironment Parameters

The engineered probes are utilized to interrogate the TME. A critical pathway involves hypoxia-induced signaling.

Diagram Title: Hypoxia Signaling & NIR-II Probe Activation in TME

Experimental Protocol 4.1: NIR-II Imaging of Tumor Vasculature (EPR Effect)

• Probe Injection: Tail-vein inject 200 µL of PBS containing 100 pmol of PEG-coated Ag₂S QDs or citric acid-coated RENPs into a mouse bearing a subcutaneous tumor (~200 mm³).
• Image Acquisition: At defined time points (e.g., 1, 4, 24 h post-injection), anesthetize the mouse. Place in an NIR-II imaging system (equipped with 808 nm or 980 nm laser and InGaAs camera).
• Acquisition Parameters: Set laser power density to 100 mW/cm², exposure time to 100-500 ms, and collect emission through a 1100 nm long-pass or 1500 nm band-pass filter.
• Data Analysis: Draw regions of interest (ROI) over the tumor and a contralateral muscle site. Calculate the tumor-to-background ratio (TBR) as (Mean IntensityTumor) / (Mean IntensityMuscle).

Research Reagent Solutions Toolkit

Table 2: Essential Materials for Inorganic NIR-II Probe Development

Reagent/Category	Example Product/Description	Primary Function in Probe Engineering
Metal Precursors	Silver acetate, Lead(II) oxide, Yttrium(III) acetate hydrate	Source of cationic elements for nanoparticle core formation.
Anion Sources	Sulfur in OLA, Trimethylsilyl fluoride, Ammonium fluoride	Provide chalcogenide or fluoride anions for crystal lattice.
Solvents & Ligands	1-Octadecene, Oleylamine, Oleic Acid	Non-polar reaction medium; act as surfactants to control growth and stabilize particles in organic phase.
Phase Transfer Polymers	Poly(maleic anhydride-alt-1-octadecene) (PMAO), Polyethylene glycol (PEG)-phospholipids	Render hydrophobic nanoparticles water-dispersible and biocompatible.
Functional Ligands	Polyacrylic acid, Citric acid, Dihydrolipoic acid	Provide carboxylate groups for subsequent bioconjugation (e.g., with peptides, antibodies).
Dopant Ions	Ytterbium(III) acetate, Erbium(III) acetate, Neodymium(III) chloride	Absorb NIR light (sensitizers, Yb³⁺, Nd³⁺) or emit at specific wavelengths (emitters, Er³⁺, Tm³⁺).
Purification Aids	Ethanol, Acetone, Amicon centrifugal filters (100 kDa MWCO)	Precipitate and wash nanoparticles to remove excess precursors and byproducts.

Experimental Workflow for Probe Development & Validation

Diagram Title: NIR-II Probe Dev Workflow

Within the development of NIR-II (1000-1700 nm) fluorescent probes for visualizing the tumor microenvironment (TME), the choice between passive and active targeting fundamentally dictates probe design and performance. Passive targeting relies on the Enhanced Permeability and Retention (EPR) effect for probe accumulation, while active targeting employs specific ligands (antibodies, peptides, small molecules) conjugated to the probe to bind overexpressed biomarkers on tumor cells or vasculature. This document details application notes and protocols for conjugating these ligands to NIR-II fluorophores (e.g., organic dyes, quantum dots, single-walled carbon nanotubes) and their subsequent evaluation.

Quantitative Comparison of Targeting Strategies

Table 1: Comparison of Passive vs. Active Targeting for NIR-II Probes

Parameter	Passive Targeting	Active Targeting (Antibody)	Active Targeting (Peptide)	Active Targeting (Small Molecule)
Primary Mechanism	EPR effect (leaky vasculature, poor drainage)	High-affinity antigen-antibody binding	Specific receptor-ligand interaction	Specific enzyme or receptor binding
Typical Size	>10 nm (Nanoparticles, aggregates)	10-20 nm (IgG conjugates)	5-10 nm (Peptide-dye conjugates)	1-3 nm (Small molecule-dye)
Conjugation Complexity	Low (Encapsulation)	High (Site-specific chemistry needed)	Moderate (Cysteine/amine coupling)	Low (Direct synthesis)
Targeting Specificity	Low (Accumulates in any leaky tissue)	Very High	High to Moderate	Moderate
Blood Clearance Rate	Slow (Long circulation)	Slow to Moderate (Fc interactions)	Fast (Rapid renal clearance)	Very Fast
Optimal NIR-II Probe Type	NIR-II polymeric nanoparticles, Ag₂S QDs	Antibody-dye conjugates, QD-antibody	Peptide-dye conjugates	Small molecule-dye conjugates
Typical Tumor-to-Background Ratio (TBR)*	2.0 - 4.0	4.0 - 10.0+	3.0 - 6.0	3.0 - 5.0
Key Challenge	Heterogeneous EPR in human tumors	Immunogenicity, large size limits penetration	Proteolytic degradation, lower affinity	Non-specific binding, rapid clearance

Reported TBR ranges from recent *in vivo NIR-II imaging studies (2023-2024).

Conjugation Strategies: Protocols

Protocol: Site-Specific Conjugation of a NIR-II Dye to a Therapeutic Monoclonal Antibody (mAb)

This protocol describes the conjugation of a DBCO-functionalized NIR-II dye (e.g., CH-1055 derivative) to an azide-modified antibody via strain-promoted alkyne-azide cycloaddition (SPAAC), preserving antigen-binding fidelity.

Research Reagent Solutions & Materials:

Item	Function
Therapeutic mAb (e.g., anti-HER2, anti-EGFR)	Targeting ligand providing specificity.
NIR-II Dye-DBCO (e.g., IR-FGP-DBCO)	Fluorophore for NIR-II imaging; DBCO enables click chemistry.
Sulfo-NHS-Azide	Reagent for introducing azide groups onto lysine residues.
Zeba Spin Desalting Columns, 7K MWCO	For buffer exchange and removal of excess reagents.
HPLC-PD-10 Desalting Column	For final purification of the conjugate.
UV-Vis-NIR Spectrophotometer	For determining degree of labeling (DOL) and concentration.
Anhydrous DMSO	Solvent for dye stock solution preparation.
1x PBS (pH 7.4), no azide	Reaction and storage buffer.

Procedure:

• Antibody Azide Modification: a. Buffer exchange the mAb (2 mg, ~13 nmol) into 1x PBS (pH 7.4) using a Zeba column. b. Dissolve Sulfo-NHS-Azide in PBS to 10 mM. Add a 20-fold molar excess (260 nmol, 26 µL) to the antibody solution. c. React for 2 hours at room temperature (RT) on a gentle rotator, protected from light. d. Purify the azide-modified antibody using a Zeba column equilibrated with PBS. Collect the eluate.

• Click Conjugation: a. Prepare a 5 mM stock of NIR-II Dye-DBCO in anhydrous DMSO. b. Add a 5-fold molar excess of dye (65 nmol, 13 µL) to the azide-modified antibody. Final DMSO concentration should be <5%. c. Incubate the reaction for 4-6 hours at RT (or overnight at 4°C) with gentle rotation, protected from light.

• Purification & Characterization: a. Purify the conjugate using an HPLC-PD-10 column with PBS as the mobile phase. Collect the colored band. b. Measure the absorbance at 280 nm (A280, protein) and at the dye's λmax (e.g., ~1050 nm, A1050). c. Calculate concentration and DOL using the formula: DOL = (A1050 / εdye1050) / [(A280 - (A1050 * CF280)) / εAb280] Where CF280 is the dye's correction factor at 280 nm, and ε are molar extinction coefficients. d. Filter sterilize (0.22 µm) and store at 4°C protected from light.

Protocol: Conjugation of a cRGD Peptide to a Carboxylated NIR-II Quantum Dot (QD)

This protocol targets αvβ3 integrin in the tumor vasculature using a cyclic RGD peptide conjugated to Ag₂S QDs via EDC/sulfo-NHS chemistry.

Research Reagent Solutions & Materials:

Item	Function
Carboxylated Ag₂S NIR-II QDs (800 nm emission)	NIR-II imaging agent with surface COOH groups.
cRGDfK Peptide (cyclo(Arg-Gly-Asp-D-Phe-Lys))	Targeting ligand for αvβ3 integrin; provides terminal amine.
EDC (1-ethyl-3-(3-dimethylaminopropyl)carbodiimide)	Activates carboxyl groups for amide bond formation.
Sulfo-NHS (N-hydroxysulfosuccinimide)	Stabilizes the activated ester intermediate.
MES Buffer (0.1 M, pH 6.0)	Optimal pH for EDC/sulfo-NHS activation.
Tris Buffer (1 M, pH 8.0)	Quenches excess EDC/NHS.
Dialysis Tubing (MWCO 10 kDa)	Purifies final conjugate from small molecules.

Procedure:

• QD Activation: a. Dilute carboxylated Ag₂S QDs (1 nmol) in 500 µL of MES buffer (pH 6.0). b. Add 500 µL of freshly prepared EDC (2 mM) and Sulfo-NHS (5 mM) in MES buffer. c. Activate for 15 minutes at RT with gentle stirring.

• Peptide Conjugation: a. Dissolve cRGDfK peptide in MES buffer to 5 mM. b. Add a 100-fold molar excess of peptide (100 nmol, 20 µL) to the activated QD solution. c. Adjust pH to ~7.5 using 1 µL increments of 0.1 M NaOH. d. React for 2 hours at RT.

• Quenching & Purification: a. Quench the reaction by adding 50 µL of Tris buffer (pH 8.0) and incubating for 15 minutes. b. Transfer the mixture to dialysis tubing (10 kDa MWCO) and dialyze against 2 L of 1x PBS for 24 hours, with 3 buffer changes. c. Recover the conjugate, filter through a 0.22 µm syringe filter, and store at 4°C in the dark.

Experimental Validation Protocol:In VivoNIR-II Imaging

Procedure for Evaluating Targeting Efficacy in a Murine Xenograft Model:

• Cell Line & Model: Subcutaneously inoculate 5x10^6 U87MG (for cRGD) or BT-474 (for anti-HER2) cells into the flanks of female nude mice. Proceed when tumors reach ~150 mm³.
• Probe Administration: Randomize mice into groups (n=5). Inject 100 µL of probe (e.g., cRGD-QD or mAb-dye conjugate, ~2 nmol dye equivalent) via the tail vein. Include a group for a non-targeted probe control (e.g., QD-COOH only).
• NIR-II Imaging: Using a NIR-II imaging system (e.g., equipped with an InGaAs camera): a. Anesthetize mice with isoflurane. b. Acquire pre-injection and serial post-injection images (e.g., 1, 4, 24, 48 h) at appropriate excitation/emission filters (e.g., 808 nm ex, 1000-1700 nm em). c. Maintain consistent imaging parameters (exposure time, laser power, field of view).
• Data Analysis: a. Draw regions of interest (ROIs) over the tumor and a contralateral muscle background. b. Calculate mean signal intensity in each ROI. c. Determine Tumor-to-Background Ratio (TBR) at each time point: TBR = Mean Signal (Tumor) / Mean Signal (Muscle). d. Perform ex vivo imaging of harvested organs to calculate %ID/g.

Visualization of Concepts and Workflows

Diagram 1: Passive vs. Active Targeting Mechanisms for NIR-II Probes

Diagram 2: Site-Specific Antibody-NIR-II Dye Conjugation Protocol

Diagram 3: In Vivo NIR-II Imaging Evaluation Workflow

The visualization of the tumor microenvironment (TME) using NIR-II (1000-1700 nm) fluorescence imaging represents a significant advance in cancer research. The NIR-II window offers superior tissue penetration and reduced autofluorescence compared to visible and NIR-I light. This application note details the design and implementation of TME-specific activatable probes for four critical TME components: angiogenic markers (e.g., VEGFR2), hypoxia (e.g., CAIX), matrix metalloproteinases (e.g., MMP-2/9), and tumor-associated macrophages (TAMs, via CD206 or MARCO). These probes enable real-time, high-resolution imaging of dynamic TME processes, facilitating research into tumor biology, therapy response, and metastatic potential.

Key Target Characteristics & Probe Design Strategies

Table 1: TME Targets and Corresponding Probe Design Strategies

TME Component	Key Molecular Target(s)	Probe Activation/ Targeting Mechanism	Typical NIR-II Fluorophore	Linker/Cleavage Sequence	Quencher (if activatable)
Angiogenesis	VEGFR2, αvβ3 Integrin	Target-binding conjugation (always-on) or MMP-activatable	CH1055, IR-1061, Ag2S QDs	PEG spacer, peptide (e.g., RGD)	N/A or BHQ-3
Hypoxia	Carbonic Anhydrase IX (CAIX), HIF-1α	Nitroreductase (NTR) enzyme reduction in low O2	IR-783 derivatives, cyanine dyes	Azo or nitroaromatic group	N/A (always-on)
Matrix Metalloproteinases	MMP-2, MMP-9	Peptide substrate cleavage (GGPLGVRGK)	IRDye 800CW, lanthanide NPs	MMP-cleavable peptide	Carbon nanotube or black hole quencher
Tumor-Associated Macrophages	CD206 (MRC1), MARCO	Receptor-specific ligand binding	SWCNTs, PbS/CdS QDs	Dextran, ox-mannose, or anti-CD206 scFv	N/A

Detailed Experimental Protocols

Protocol 3.1: Synthesis of an MMP-9 Activatable NIR-II Probe

Objective: To synthesize a probe that remains quenched until cleaved by MMP-9 in the TME, resulting in NIR-II fluorescence recovery.

Materials:

• NIR-II fluorophore-PEG-NHS ester (e.g., CH1055-PEG-NHS)
• MMP-9 substrate peptide (GGPLGVRGK) with a C-terminal cysteine and an N-terminal amine.
• Black Hole Quencher 3 (BHQ-3) maleimide.
• Anhydrous DMF, DPBS, dialysis tubing (MWCO 3.5 kDa).

Procedure:

• Peptide-Quencher Conjugation: Dissolve 5 µmol of peptide in 1 mL of degassed PBS. Add 5.5 µmol of BHQ-3 maleimide dissolved in 100 µL DMF dropwise while stirring. React under nitrogen at room temperature for 4 hours. Purify via HPLC.
• Fluorophore Conjugation: Dissolve 4 µmol of purified peptide-BHQ3 conjugate and 4.4 µmol of CH1055-PEG-NHS in 2 mL of anhydrous DMF with 10 µL of triethylamine. Stir in the dark for 12 hours at room temperature.
• Purification: The reaction mixture is diluted with water and dialyzed against DPBS (pH 7.4) for 48 hours with frequent buffer changes. Lyophilize the final product.
• Validation: Confirm molecular weight via MALDI-TOF. Test activation by incubating 10 µM probe with 100 ng/mL recombinant MMP-9 in assay buffer (50 mM Tris, 10 mM CaCl2, pH 7.5) at 37°C. Measure NIR-II fluorescence (ex: 808 nm, em: 1000-1300 nm) over 2 hours.

Protocol 3.2: In Vivo Imaging of Hypoxia with a NTR-Activatable Probe

Objective: To image hypoxic regions in a murine tumor model using a nitroreductase-responsive NIR-II probe.

Materials:

• NTR-activatable probe (e.g., Cy7-based derivative with nitroimidazole).
• Mouse model with subcutaneous tumor (e.g., 4T1 breast carcinoma).
• NIR-II imaging system (e.g., InGaAs camera with 808 nm laser).
• Pimonidazole HCl (hypoxia marker for validation).

Procedure:

• Probe Administration: When tumor volume reaches ~300 mm³, inject 100 µL of probe solution (2 nmol in PBS) intravenously via the tail vein.
• Image Acquisition: Anesthetize the mouse with isoflurane. Acquire pre-injection baseline NIR-II images. Acquire serial images at 1, 2, 4, 6, 12, and 24 hours post-injection using consistent exposure settings.
• Ex Vivo Validation: At 24 hours, sacrifice the mouse. Administer pimonidazole (60 mg/kg, i.p.) 1 hour prior. Excise tumor and major organs. Image ex vivo for probe distribution. Section tumor tissue and co-stain for pimonidazole adducts (hypoxyprobe antibody) and CAIX (immunofluorescence) to correlate probe signal with hypoxic regions.
• Data Analysis: Draw regions of interest (ROIs) over the tumor and a contralateral muscle site. Calculate tumor-to-background ratio (TBR) as (Mean Fluorescence Intensity_Tumor) / (Mean Fluorescence Intensity_Muscle).

Protocol 3.3: Targeting Tumor-Associated Macrophages with Mannose-Coated Nanoprobes

Objective: To image TAMs in vivo using mannose-functionalized NIR-II quantum dots.

Materials:

• PbS/CdS core/shell QDs emitting at 1300 nm.
• α-D-mannopyranosylphenyl isothiocyanate.
• Poly(maleic anhydride-alt-1-octadecene) (PMAO) for phase transfer.
• Bifunctional PEG (NH2-PEG-COOH).

Procedure:

• QD Functionalization: Ligand-exchange hydrophobic QDs with PMAO to make them water-soluble. Conjugate NH2-PEG-COOH to QD surface via EDC/NHS chemistry.
• Mannose Conjugation: Activate the terminal carboxyl groups of the PEG on the QDs with EDC/sulfo-NHS. React with the isothiocyanate group of α-D-mannopyranosylphenyl isothiocyanate in borate buffer (pH 9.0) overnight. Purify by size-exclusion chromatography.
• In Vitro Validation: Incubate probes with RAW 264.7 macrophages pre-polarized to an M2 phenotype with IL-4. Perform competitive binding assays with free α-mannose. Analyze by flow cytometry and confocal microscopy.
• In Vivo Imaging: Administer 200 µL of probe (1 µM QD concentration) intravenously to tumor-bearing mice. Image at 6, 12, and 24 hours. For specificity control, pre-inject a blocking dose of free mannan (20 mg/kg) 30 minutes prior to probe injection.

Visualization of Pathways and Workflows

TME Component Activation of NIR-II Probes

Experimental Workflow for TME Probe Validation

The Scientist's Toolkit: Research Reagent Solutions

Table 2: Essential Materials for TME-Specific NIR-II Probe Development

Category	Item/Reagent	Function & Application Note
Fluorophores	CH1055, IR-1061, IR-26 Dye	Organic NIR-II fluorophores with emission 1000-1400 nm. Require pegylation for solubility.
	Ag2S, PbS/CdS Quantum Dots	Inorganic nanoprobes with high quantum yield and tunable NIR-II emission. Excellent for conjugation.
	Single-Walled Carbon Nanotubes (SWCNTs)	NIR-II emitters with inherent sensitivity to local environment. Ideal for sensor design.
Targeting Moieties	cRGDfk peptide	Cyclic arginine-glycine-aspartic acid peptide for targeting αvβ3 integrin on angiogenic vasculature.
	Sulfonamide-based inhibitors (e.g., Acetazolamide)	High-affinity ligands for Carbonic Anhydrase IX (CAIX), a hypoxia marker.
	MMP-substrate peptides (PLGVR, GPLGVRGK)	Cleavable linkers for constructing activatable probes specific for MMP-2/9.
	Mannose, Dextran, anti-CD206 scFv	Targeting ligands for the mannose receptor (CD206) on M2-polarized TAMs.
Chemical Tools	BHQ-3, Carbon Nanotube Quenchers	Efficient quenchers for NIR-II fluorescence, used in activatable "smart" probes.
	PEG Linkers (NH2-PEG-COOH, MAL-PEG-NHS)	Improve biocompatibility, prolong circulation, and provide functional groups for bioconjugation.
	Nitroimidazole or Azo-based compounds	Serve as hypoxia-sensitive triggers, reduced by nitroreductase (NTR) in low oxygen.
Assay Kits	Recombinant Human MMP-2/9	For in vitro validation of probe activation kinetics and specificity.
	Hypoxyprobe-1 (Pimonidazole HCl)	Gold standard for immunohistochemical validation of tumor hypoxia.
	IL-4/IL-13 Cytokine Mix	For in vitro polarization of macrophages to an M2 phenotype (TAM-like).
Imaging Equipment	InGaAs NIR-II Camera	Essential detector for capturing 1000-1700 nm fluorescence with high sensitivity.
	808 nm or 980 nm Laser Diode	Common excitation sources for NIR-II fluorophores, offering good tissue penetration.
	Isoflurane Anesthesia System	For maintaining stable anesthesia during longitudinal in vivo imaging sessions.

This protocol details the in vivo application of near-infrared window II (NIR-II, 1000-1700 nm) fluorescent probes for high-resolution visualization of the tumor microenvironment (TME). Within the broader thesis, these protocols establish a standardized framework for quantifying dynamic TME parameters—including vascular heterogeneity, permeability, interstitial fluid pressure, and immune cell infiltration—using the superior tissue penetration and reduced autofluorescence of NIR-II light. The goal is to enable precise, longitudinal monitoring of TME responses to therapeutic interventions.

Animal Preparation Protocol

2.1 Tumor Model Establishment

• Cell Line Selection: Choose syngeneic (e.g., 4T1 murine breast carcinoma) or xenograft (e.g., U87MG human glioblastoma) models relevant to the TME research question.
• Inoculation: Harvest and resuspend cells in sterile PBS or Matrigel (1:1 ratio for improved tumorigenicity). For subcutaneous models, inject 50-100 µL containing 0.5-2 x 10^6 cells into the dorsal flank of anesthetized mice (e.g., 6-8 week-old female BALB/c or nude mice). For orthotopic models, follow organ-specific surgical procedures.
• Monitoring: Allow tumors to grow until they reach a target volume of 100-200 mm³ (calculated as Volume = (Length x Width²)/2). This typically takes 7-14 days and provides a developed TME.

2.2 Pre-Imaging Animal Preparation

• Anesthesia Induction & Maintenance: Induce anesthesia with 3-4% isoflurane in 100% oxygen, maintain at 1-2% via nose cone for imaging. Continuously monitor respiration rate.
• Hair Removal & Positioning: Completely remove hair from the imaging area (tumor and background) using electric clippers followed by a depilatory cream to minimize scattering. Apply ophthalmic ointment to prevent corneal drying. Securely position the mouse in the imaging chamber using medical tape, ensuring the tumor region is unobstructed.
• Physiological Monitoring: Maintain body temperature at 37°C ± 0.5°C using a feedback-controlled heating pad throughout the procedure.

Table 1: Summary of Common Tumor Models for NIR-II TME Imaging

Model Type	Example Cell Line	Host Mouse	Inoculation Site	Typical TME Features
Syngeneic	4T1 (Breast CA)	BALB/c	Subcutaneous Flank	Immunocompetent, fibrotic, heterogeneous vasculature
Xenograft	U87MG (Glioblastoma)	Athymic Nude	Subcutaneous or Intracranial	Immunodeficient, angiogenic, necrotic core
PDX (Patient-Derived Xenograft)	Various Cancers	NSG	Subcutaneous or Orthotopic	Retains human TME heterogeneity & stroma

Probe Dose Optimization Protocol

3.1 Rationale for Optimization Optimal signal-to-background ratio (SBR) depends on probe pharmacokinetics, tumor targeting efficiency, and clearance rates. Dose optimization balances maximal target saturation against minimal non-specific background.

3.2 Experimental Design for Dose Finding

• Probe Administration: Dilute the NIR-II probe (e.g., IRDye800CW conjugate, CH1055, or Ag2S quantum dots) in sterile PBS. Inject intravenously via the tail vein at varying doses (e.g., 1, 2, 5, 10 nmol per mouse) into cohorts of tumor-bearing mice (n=3 per group).
• Image Acquisition: Acquire longitudinal images pre-injection and at serial time points post-injection (e.g., 1, 3, 6, 12, 24h) using consistent imaging parameters (laser power, exposure time, filters).
• Quantitative Analysis: Using region-of-interest (ROI) analysis software, quantify mean fluorescence intensity (MFI) in the tumor (T) and a contralateral background (B) muscle region. Calculate SBR = MFIT / MFIB and tumor-to-liver ratio (TLR) to assess specificity.

3.3 Determination of Optimal Dose & Imaging Window The optimal dose yields the highest peak SBR with an acceptable TLR (indicating good clearance from metabolic organs). The time point of peak SBR defines the optimal imaging window.

Table 2: Example Dose Optimization Results for a NIR-II Antibody Conjugate

Dose (nmol/mouse)	Peak SBR (Mean ± SD)	Time to Peak SBR (h)	Tumor-to-Liver Ratio at 24h	Recommended for Imaging?
1.0	2.1 ± 0.3	12	1.8	No (Low Signal)
2.0	3.5 ± 0.4	12	1.5	Yes (Optimal)
5.0	3.7 ± 0.5	24	0.9	No (High Liver Retention)
10.0	3.8 ± 0.6	24	0.6	No (High Liver Retention)

NIR-II Probe Dose Optimization Workflow (97 chars)

In Vivo Data Acquisition Protocol

4.1 NIR-II Imaging System Setup

• Instrument Calibration: Power on the NIR-II imaging system (e.g., custom-built or commercial). Allow laser(s) (e.g., 808 nm, 980 nm) to stabilize. Perform a dark current calibration by capturing an image with the lens cap on.
• Parameter Standardization: Set parameters based on probe excitation/emission: Laser power (50-100 mW/cm²), exposure time (50-300 ms), binning (2x2), and emission filters (e.g., 1000 nm long-pass or 1100/1500 nm bandpass). Keep these constant for all experiments in a series.

4.2 Image Acquisition Workflow

• Acquire a pre-injection background image of the anesthetized, positioned mouse.
• Administer the optimized dose of NIR-II probe via tail vein injection.
• Initiate dynamic imaging for the first 5-10 minutes (e.g., 1 frame/10s) to capture pharmacokinetic uptake.
• Continue longitudinal imaging at the predetermined optimal time points (e.g., 1, 6, 24h). For each session, re-anesthetize and position the mouse identically.
• Acquire ex vivo images of excised tumors and major organs at the terminal time point for biodistribution analysis.

4.3 Data Processing & Analysis

• Background Subtraction: Subtract the pre-injection image from all subsequent images using image analysis software (e.g., ImageJ, Living Image).
• ROI Definition: Manually or automatically define ROIs for the entire tumor, specific TME regions (e.g., periphery vs. core), background tissue, and key organs.
• Quantification: Extract MFI and total fluorescence (TF) for each ROI. Generate time-intensity curves and calculate standard metrics: SBR, Target-to-Background Ratio (TBR), and percentage of injected dose per gram of tissue (%ID/g) for ex vivo samples.

In Vivo NIR-II Data Acquisition Workflow (81 chars)

The Scientist's Toolkit: Essential Research Reagents & Materials

Table 3: Key Research Reagent Solutions for NIR-II TME Imaging

Item	Function/Application	Example Product/Note
NIR-II Fluorescent Probe	The imaging agent that emits in the NIR-II window. Conjugated to targeting ligands (antibodies, peptides) or untargeted (e.g., indocyanine green derivative).	CH1055-PEG, IRDye800CW, Ag2S Quantum Dots, LZ1105.
Matrigel (Growth Factor Reduced)	Basement membrane matrix used for co-injection with tumor cells to enhance engraftment and support TME development.	Corning #356231. Thaw on ice overnight.
Isoflurane, USP	Volatile anesthetic for safe, reversible induction and maintenance of anesthesia during imaging procedures.	Pharmaceutical grade, used with a calibrated vaporizer.
Sterile PBS (1X), pH 7.4	Universal diluent for preparing cell suspensions and probe formulations for in vivo injection.	Without Ca2+/Mg2+ for injection compatibility.
Hair Removal Cream	Critical for removing fur to prevent photon scattering and absorption, which drastically improves image clarity and quantitation.	Nair or equivalent; apply for <1 min and wipe clean.
Ophthalmic Ointment	Protects corneas from drying out during prolonged anesthesia under imaging laser light.	Puralube Vet Ointment or equivalent.
Fluorescence Reference Standard	A stable, fluorescent material (e.g., solid epoxy resin block) for normalizing fluorescence intensity across imaging sessions.	Essential for longitudinal study reproducibility.
Image Analysis Software	For quantifying fluorescence intensity, defining ROIs, and generating pharmacokinetic curves from raw imaging data.	ImageJ/Fiji, LI-COR Image Studio, PerkinElmer Living Image.

Introduction Within the broader thesis on NIR-II probes for tumor microenvironment (TME) research, activatable multimodal agents represent a pivotal advancement. These probes synergize the deep-tissue, high-resolution anatomical imaging of NIR-II fluorescence with the functional and metabolic insights of photoacoustic imaging or the localized efficacy of therapeutic payloads. This integration enables real-time, multiplexed visualization of TME biomarkers (e.g., pH, enzymes, hypoxia) alongside precise therapeutic intervention, moving beyond mere detection to theranostics.

Application Notes

Note 1: Rationetric NIR-II/PA Probe for pH Sensing in the TME

• Principle: A probe constructed from a pH-sensitive NIR-II fluorophore (e.g., a benzo[b]thiophene-derived dye) and a pH-insensitive reference dye (e.g., a cyanine-based PA agent) covalently linked. In the acidic TME, the NIR-II fluorescence quenches while the PA signal remains constant, providing a built-in calibration via the fluorescence/PA ratio.
• Key Finding: Enables quantitative pH mapping with a penetration depth exceeding 5 mm and a spatial resolution of ~150 µm for PA and ~40 µm for NIR-II fluorescence.
• Data Summary:

Note 2: Enzyme-Activatable Probe for NIR-II Fluorescence-Guided Photothermal Therapy (PTT)

• Principle: A silent probe (quenched NIR-II fluorescence and PA) is activated by TME-overexpressed enzymes (e.g., Cathepsin B). Cleavage restores both signals, allowing precise tumor delineation via NIR-II imaging and subsequent high-spatial-resolution PA imaging for temperature monitoring during PTT.
• Key Finding: Provides >90% tumor growth inhibition in murine models with minimal damage to surrounding tissue, as the activated probe confines the photothermal effect to the tumor.
• Data Summary:

Experimental Protocols

Protocol 1: Synthesis and Characterization of a Dual-Modal NIR-II/PA Probe (Example: MMP-9 Activatable)

• Objective: Synthesize a matrix metalloproteinase-9 (MMP-9) responsive probe for simultaneous NIR-II fluorescence and PA imaging.
• Materials: See Scientist's Toolkit.
• Procedure:
  • Conjugation: Dissolve the NIR-II dye-PEG₄-Cys and the PA dye-PEG₄-Cys in anhydrous DMSO (1:1 molar ratio). Add a 5-fold molar excess of the MMP-9 cleavable peptide linker (GPLGVRGK). React under argon with HATU and DIPEA for 12 hours at room temperature.
  • Purification: Purify the crude product via reverse-phase HPLC (C18 column, water/acetonitrile gradient with 0.1% TFA). Lyophilize the collected fraction to obtain the purified probe.
  • Validation: Confirm molecular weight via MALDI-TOF mass spectrometry. Measure absorbance and emission spectra in PBS. Confirm MMP-9 activation by incubating 10 µM probe with 100 nM recombinant MMP-9 in assay buffer at 37°C for 2 hours and re-measuring spectra.

Protocol 2: In Vivo Dual-Modal Imaging of Tumor MMP-9 Activity

• Objective: Visualize and quantify MMP-9 activity in a subcutaneous tumor mouse model.
• Materials: See Scientist's Toolkit.
• Procedure:
  • Animal Model: Inoculate 1x10⁶ tumor cells (e.g., HT-1080, high MMP-9) into the flank of a nude mouse. Proceed at tumor volume of ~150 mm³.
  • Probe Administration: Inject the purified probe (2.5 mg/kg in 100 µL saline) via tail vein.
  • NIR-II Fluorescence Imaging: At specified time points (e.g., 0, 2, 6, 24 h post-injection), anesthetize the mouse. Acquire images using a 1064 nm laser for excitation and a 1100 nm long-pass filter with an InGaAs camera. Quantify signal-to-noise ratio (SNR) in tumor vs. muscle.
  • Photoacoustic Imaging: Immediately after fluorescence imaging, transfer the mouse to the PA system. Acquire 3D PA images at the peak absorption wavelength of the activated probe (e.g., 780 nm). Co-register with ultrasound images.
  • Ex Vivo Validation: Sacrifice the mouse. Harvest tumors and major organs for ex vivo imaging and histological analysis (H&E, MMP-9 IHC).

The Scientist's Toolkit

Table 3: Essential Research Reagents and Materials.

Item	Function/Description
NIR-II Fluorophore (e.g., CH1055 derivative)	Core imaging component; emits in the 1000-1700 nm window for deep-tissue fluorescence.
PA Agent (e.g., ICG derivative, Semiconducting Polymer Nanoparticle)	Core imaging component; strong NIR absorber for generating photoacoustic signals.
Activatable Linker (e.g., MMP-9 cleavable peptide)	Provides specificity; remains intact until cleaved by the target TME biomarker.
PEG Spacer	Improves probe solubility, pharmacokinetics, and reduces non-specific binding.
HATU/DIPEA	Coupling reagents for conjugating dye, linker, and PEG components.
Small Animal NIR-II Fluorescence Imager	System equipped with a 1064 nm laser and a cooled InGaAs camera for in vivo imaging.
Multispectral Optoacoustic Tomography (MSOT) System	System for acquiring 3D, spectrally resolved photoacoustic images in real-time.

Visualizations

Diagram 1: Workflow of an enzyme-activatable multimodal probe.

Diagram 2: Experimental protocol for validating a multimodal probe.

Overcoming Technical Hurdles: A Guide to Optimizing NIR-II Imaging Fidelity and Specificity

Within the broader thesis on advancing NIR-II (1000-1700 nm) fluorescence imaging for tumor microenvironment (TME) research, this application note addresses three pervasive artifacts: background noise from tissue autofluorescence, signal attenuation due to tissue absorption/scattering, and non-specific signal from probe aggregation. Effective management of these artifacts is critical for quantifying true probe biodistribution and target engagement in vivo. We present standardized protocols and reagent solutions to enhance signal-to-noise ratio (SNR) and quantification accuracy.

Quantifying and Mitigating Artifacts: A Data-Driven Approach

The following table summarizes key artifact sources, their impact on NIR-II imaging, and quantitative benchmarks for mitigation.

Table 1: Common Artifacts in NIR-II TME Imaging & Mitigation Metrics

Artifact Category	Primary Source	Impact on SNR (Typical Reduction)	Key Mitigation Strategy	Expected Improvement (Post-Mitigation)
Background Noise	Tissue autofluorescence (e.g., collagen, elastin, lipids)	40-60% in 700-900 nm range; <10% in >1100 nm	Spectral unmixing; Long-pass filtering (>1100 nm)	SNR increase of 5- to 10-fold in NIR-IIa/b windows
Tissue Absorption	Water (peak ~1450 nm), hemoglobin, lipids	Absorption coefficient (μa) of H₂O: ~0.3 cm⁻¹ at 1100 nm, ~1.2 cm⁻¹ at 1450 nm	Imaging within "biological windows" (NIR-IIa: 1300-1400 nm; NIR-IIb: 1500-1700 nm)	Penetration depth up to 5-8 mm in NIR-IIb vs 1-3 mm in NIR-I
Probe Aggregation	Hydrophobic interactions; Protein corona formation in vivo	Uncontrolled aggregation can cause >80% signal quenching and false-positive accumulation	Surface PEGylation; Zwitterionic coating; Size-exclusion purification pre-injection	Aggregation-induced quenching reduced by >90%; Improved tumor-to-background ratio (TBR) by 2-4x

Experimental Protocols

Protocol 2.1: System Calibration for Background Subtraction

Objective: To establish and subtract system- and tissue-specific background for quantitative NIR-II imaging. Materials: NIR-II imaging system, wavelength-filtered light source, healthy control mouse, black calibration standard. Procedure:

• System Dark Noise Capture: Cap the lens, acquire a 5-minute exposure image. This is your dark frame.
• Flat-Field Correction: Image a uniformly fluorescent reference slide under identical settings to your experiment. This is your flat field.
• Tissue Autofluorescence Baseline: Anesthetize a healthy control mouse. Acquire in vivo images at all experimental wavelengths (e.g., 1100 nm, 1300 nm, 1500 nm LP).
• Image Processing: Apply correction: Corrected Image = (Raw Image - Dark Frame) / (Flat Field - Dark Frame).
• Spectral Unmixing: Using software (e.g., MATLAB, ImageJ), subtract the weighted autofluorescence spectrum (from step 3) from the experimental image based on reference spectra.

Protocol 2.2: Assessing Probe Aggregation State Pre-Injection

Objective: To ensure monodispersity of NIR-II probes prior to in vivo administration. Materials: Dynamic Light Scattering (DLS) instrument, Size-Exclusion Chromatography (SEC) system, purified probe solution. Procedure:

• DLS Measurement: Dilute probe in 1x PBS (or relevant buffer) to 0.1 mg/mL. Load into cuvette.
• Perform 3 measurements at 25°C. The polydispersity index (PDI) must be <0.2. A high PDI indicates aggregation.
• SEC Validation: Inject 50 µL of probe solution (1 mg/mL) onto a calibrated SEC column (e.g., Superdex 200). Elute with PBS at 0.5 mL/min.
• The chromatogram should show a single, sharp elution peak. Collect the main peak fraction for injection.
• Post-Filtration: Pass the probe solution through a sterile, 0.22 µm syringe filter immediately before tail vein injection.

Protocol 2.3: In Vivo Validation of Target-Specific Signal vs. Aggregation Artifact

Objective: To differentiate true tumor accumulation from passive accumulation due to aggregation (Enhanced Permeability and Retention - EPR). Materials: Target-positive and isogenic target-negative tumor models, specific NIR-II probe, non-targeted control probe (same core material). Procedure:

• Implant both tumor models in opposite flanks of the same mouse (n=5).
• Adminulate the specific NIR-II probe via tail vein (dose: e.g., 2 nmol in 100 µL PBS).
• Acquire longitudinal NIR-II images at 1, 4, 24, and 48 h post-injection (p.i.) using consistent parameters (exposure, filter).
• At 48 h p.i., sacrifice mice, excise tumors and major organs. Image ex vivo and quantify fluorescence intensity per mg tissue.
• Data Analysis: True target engagement is confirmed if signal in the target-positive tumor is significantly (>2x) higher than in the target-negative tumor and higher than the signal from the non-targeted control probe in the positive tumor.

Visualization of Methodologies

Title: NIR-II Image Processing Workflow for Artifact Reduction

Title: Probe Aggregation Impact on In Vivo Interpretation

The Scientist's Toolkit: Research Reagent Solutions

Table 2: Essential Materials for Managing NIR-II Artifacts

Item / Reagent	Function & Rationale	Example Product / Specification
NIR-IIb Long-Pass Filters	Blocks light below 1500-1600 nm, drastically reducing tissue autofluorescence and scattering noise for deep-tissue imaging.	Thorlabs FELH1600, Semrock BLP01-1550R-25.
Zwitterionic Coating Ligands	Surface modification for probes to prevent protein corona formation and aggregation, ensuring stable hydrodynamic size in serum.	HS-PEG-CK, ligands based on carboxybetaine or sulfobetaine.
Size-Exclusion Chromatography Columns	Critical for pre-injection purification to remove aggregates and ensure only monodisperse probe fractions are administered.	Cytiva Superdex 200 Increase, analytical or preparative grade.
Reference Dye (Non-Targeted)	A control dye with similar optical properties but no targeting moiety, essential for distinguishing EPR effect from specific binding.	PEGylated IRDye 1500CW or non-targeted Ag₂S nanodots.
Spectral Unmixing Software	Enables mathematical separation of probe signal from persistent tissue autofluorescence based on reference spectra.	ImageJ with Linear Unmixing plugin, MATLAB spectral unmixing toolbox.
Anisotropy Measurement Kit	To monitor changes in probe rotational diffusion, an early indicator of aggregation or non-specific binding in complex media.	Fluorescence polarization/anisotropy kit with NIR-compatible filters.

Introduction: A Thesis Context on NIR-II Probes for Tumor Microenvironment Imaging Within the development of NIR-II (1000-1700 nm) fluorescent probes for high-resolution imaging of the tumor microenvironment (TME), two parameters are paramount: quantum yield (QY, brightness) and photostability. Improvements directly enhance signal-to-noise ratio, penetration depth, and longitudinal tracking capability. This application note details material innovations and formulation strategies to address these challenges, providing actionable protocols for researchers.

Material Design Strategies: A Quantitative Summary Recent advances in materials engineering have yielded significant improvements in NIR-II probe performance. Key strategies include core-shell engineering, surface ligand engineering, and molecular aggregation control.

Table 1: Material Strategies for NIR-II Probe Optimization

Strategy	Material Example	Reported Quantum Yield (QY)	Reported Photostability (Remaining Fluorescence)	Key Mechanism
Core-Shell Engineering	PbS/CdS Core/Shell Quantum Dots (QDs)	~10-15% (NIR-II)	>80% after 1h @ 808nm, 0.5 W/cm²	Shell passivates surface traps, reduces non-radiative decay.
Polymer Coating/Encapsulation	IR-1061 encapsulated in Pluronic F-127/PLGA nanoparticles	N/A (enhancement factor ~5x)	>70% after 30 min laser exposure	Physical barrier against oxygen/moisture; reduces molecular motion.
Rigid Matrix Incorporation	ICG derivatives in Bovine Serum Albumin (BSA) matrix	Up to ~11% (vs. ~0.2% for free dye)	Highly stable; matrix prevents photoisomerization.	Restricts intramolecular motion (RIM), suppresses vibronic decay.
Molecular Packing Control	Donor-Acceptor-Donor (D-A-D) small molecules with branched side chains	Up to ~5.3% in aqueous NPs	>60% after 10 min @ 0.8 W/cm²	Inhibits aggregation-caused quenching (ACQ) and promotes aggregation-induced emission (AIE).
Surface Ligand Exchange	Ag₂S QDs with short, compact ligands (e.g., glutathione)	Up to ~15.9% in water	Improved vs. long-chain ligands	Reduces Förster resonance energy transfer (FRET) quenching between proximal QDs.

Detailed Experimental Protocols

Protocol 1: Synthesis of Highly Photostable, High-QY PbS/CdS Core/Shell QDs Objective: To synthesize NIR-II-emitting QDs with a protective CdS shell for enhanced photostability and QY. Reagents: Lead oxide (PbO), Oleic acid (OA), 1-Octadecene (ODE), Bis(trimethylsilyl) sulfide (TMS)₂S, Cadmium oxide (CdO), Caution: All procedures require standard Schlenk line techniques under inert atmosphere. Procedure:

• Core Synthesis: In a 50 mL three-neck flask, mix PbO (0.45 mmol), OA (1.5 mL), and ODE (10 mL). Heat to 120°C under vacuum for 1h. Switch to N₂ atmosphere and raise temperature to 150°C until the solution becomes clear.
• Quickly inject a solution of (TMS)₂S (0.3 mmol) in ODE (2 mL). Let the reaction proceed for 30-60 seconds to form PbS cores.
• Rapidly cool the reaction mixture to 70°C using a water bath.
• Shell Growth: Prepare a separate Cd-OA precursor (CdO: 0.9 mmol, OA: 2.4 mL, ODE: 10 mL, degassed at 120°C). Using a syringe pump, slowly inject (~2 mL/hr) this Cd-OA precursor and a separate (TMS)₂S/ODE solution simultaneously into the PbS core solution at 70°C with vigorous stirring.
• After injection, anneal at 90°C for 30 minutes. Cool to room temperature.
• Purify by precipitation with ethanol/acetone, followed by centrifugation. Redisperse in chloroform or a non-polar solvent.

Protocol 2: Formulation of NIR-II Dyes into AIE-Active Nanoparticles (NPs) via Nano-precipitation Objective: To encapsulate hydrophobic D-A-D NIR-II dyes into stable, water-dispersible nanoparticles that exhibit high QY via the RIM mechanism. Reagents: Hydrophobic NIR-II dye (e.g., CH1055 derivative), DSPE-PEG2000, Tetrahydrofuran (THF), Deionized water. Procedure:

• Prepare the organic phase: Dissolve the NIR-II dye (0.5 mg) and DSPE-PEG2000 (5 mg) in THF (1 mL). Sonicate until clear.
• Prepare the aqueous phase: Filter deionized water (5 mL) through a 0.22 µm membrane.
• Using a syringe pump, rapidly inject the organic phase (1 mL) into the stirred aqueous phase (5 mL) at a rate of 1 mL/min.
• Stir the mixture vigorously for 3 hours at room temperature to allow complete evaporation of THF and formation of stable NPs.
• Concentrate the NP suspension using an ultracentrifugation filter (MWCO 100 kDa) at 4000 rpm for 10 minutes. Wash twice with water to remove residual THF and free ligands.
• Filter the final NP suspension through a 0.22 µm syringe filter. Characterize size via DLS and fluorescence properties.

Visualization of Strategies and Workflows

Title: Material Strategies to Improve NIR-II Probe Performance

Title: Workflow for NIR-II Dye Nano-Precipitation

The Scientist's Toolkit: Essential Research Reagent Solutions

Table 2: Key Reagents for NIR-II Probe Optimization

Reagent/Material	Supplier Examples	Function in Optimization
Pluronic F-127	Sigma-Aldrich, BASF	Amphiphilic polymer for encapsulating dyes; forms micelles that provide a protective physical barrier.
DSPE-PEG2000	Avanti Polar Lipids, NOF America	PEGylated lipid for nanoparticle formulation; confers water solubility and stealth properties.
Bovine Serum Albumin (BSA)	Sigma-Aldrich, Thermo Fisher	Protein matrix to rigidly encapsulate dyes via hydrophobic interaction, enabling RIM.
Glutathione (Reduced)	Sigma-Aldrich, Tokyo Chemical Industry	Short, compact ligand for QD surface exchange; reduces inter-particle quenching.
1-Octadecene (ODE)	Sigma-Aldrich, Acros Organics	High-boiling, inert solvent for high-temperature synthesis of QDs and nanocrystals.
Oleic Acid (OA)	Sigma-Aldrich, Alfa Aesar	Common surface ligand and reaction solvent in nanomaterial synthesis; provides colloidal stability.

In the context of developing NIR-II (1000-1700 nm) fluorescent probes for visualizing the tumor microenvironment, optimizing pharmacokinetics is paramount. The efficacy of these probes hinges on a critical balance: achieving prolonged systemic circulation to allow for sufficient tumor exposure, maximizing active accumulation within the tumor via the Enhanced Permeability and Retention (EPR) effect and/or active targeting, while ensuring eventual clearance to minimize background signal and long-term toxicity. This document provides application notes and detailed protocols for evaluating and tuning these key pharmacokinetic parameters.

Key Pharmacokinetic Parameters & Quantitative Data

The performance of NIR-II probes is evaluated against several quantitative metrics. The following table summarizes target ranges and typical values for optimized probes based on recent literature.

Table 1: Key Pharmacokinetic Parameters for NIR-II Tumor Imaging Probes

Parameter	Description	Optimal Range / Target Value	Measurement Technique
Circulation Half-life (t₁/₂,β)	Time for probe concentration in blood to reduce by half in the elimination phase.	> 3 - 6 hours (for passive EPR targeting)	Blood sampling & ex vivo NIR-II measurement or in vivo fluorescence pharmacokinetics.
Tumor Accumulation (%ID/g)	Percentage of injected dose per gram of tumor tissue at peak uptake.	> 5 - 10 %ID/g (for high signal-to-background)	Ex vivo biodistribution study using weighted tissues.
Peak Tumor Uptake Time	Time post-injection when tumor accumulation reaches maximum.	6 - 24 hours	Time-series in vivo imaging or ex vivo biodistribution.
Tumor-to-Background Ratio (TBR)	Ratio of fluorescence intensity in tumor vs. adjacent normal tissue or muscle.	> 5 at peak time	Region-of-interest analysis from in vivo NIR-II images.
Clearance Pathway	Primary route of elimination from the body.	Renal (preferred for rapid clearance) or Hepatic	Biodistribution analysis of kidneys, liver, and intestines.
Blood Clearance Rate	Rate constant for elimination from bloodstream (k_el).	Tuned to balance accumulation and clearance.	Calculated from pharmacokinetic curve fitting.

Research Reagent Solutions & Essential Materials

Table 2: Scientist's Toolkit for Pharmacokinetic Optimization Studies

Item	Function in Research
NIR-II Probe Library	Variants with different sizes (e.g., 5-20 nm nanoparticles, small molecules), surface charges (neutral, negative), and surface chemistries (PEGylated, targeted ligands).
PEGylation Reagents (e.g., mPEG-NHS)	To conjugate polyethylene glycol (PEG) chains to probes, reducing opsonization and extending circulation half-life.
Targeting Ligands (e.g., cRGD, Anti-EGFR)	Antibodies, peptides, or small molecules conjugated to probes to promote active tumor accumulation via receptor-mediated endocytosis.
Animal Tumor Models	Subcutaneous or orthotopic tumor-bearing mice (e.g., 4T1, U87MG). Essential for in vivo pharmacokinetic and biodistribution studies.
NIR-II In Vivo Imaging System	Equipped with a 808/980 nm laser for excitation and an InGaAs camera for detection of 1000-1700 nm emission.
Microcentrifuge & Ultrafiltration Devices (MWCO)	For separating free dye, purifying probes, and measuring protein binding.
ICP-MS or Radioisotope Labeling	For quantitative biodistribution studies independent of fluorescence quenching.
Pharmacokinetic Modeling Software	(e.g., PK Solver) to fit blood concentration-time data and calculate key parameters (AUC, t₁/₂, CL).

Detailed Experimental Protocols

Protocol 4.1: Measuring Blood Circulation Half-Life

Objective: To determine the systemic clearance rate of the NIR-II probe. Materials: NIR-II probe in PBS, mouse tail vein catheter, heparinized capillary tubes, NIR-II fluorimeter or plate reader. Procedure:

• Administer probe via tail vein injection (dose: ~100 µL of 0.1-1 mg/mL solution) to tumor-bearing mice (n=3-5).
• Collect blood samples (~10 µL) from the retro-orbital plexus or tail nick into heparinized tubes at time points: 1 min, 5 min, 15 min, 30 min, 1h, 2h, 4h, 8h, 12h, 24h post-injection.
• Lyse each sample in 1% PBS / Triton X-100. Centrifuge to remove debris.
• Measure NIR-II fluorescence intensity of supernatant using a fluorimeter with appropriate NIR-II filters.
• Plot fluorescence intensity (converted to concentration via standard curve) vs. time.
• Fit the elimination phase (log-linear) to calculate the terminal half-life (t₁/₂,β) using pharmacokinetic software.

Protocol 4.2: Quantitative Biodistribution for Tumor Accumulation & Clearance

Objective: To quantify probe accumulation in tumors and major organs over time. Materials: Dissection tools, precision balance, homogenizer, NIR-II imaging system or fluorimeter. Procedure:

• At predetermined time points (e.g., 4h, 12h, 24h, 48h) post-injection, euthanize mice (n=5 per time point).
• Harvest tumor, heart, liver, spleen, lungs, kidneys, intestines, muscle, and skin. Weigh each tissue precisely.
• Homogenize each tissue in 1 mL of PBS (or lysis buffer) on ice.
• Centrifuge homogenates at 12,000 rpm for 10 min.
• For NIR-II measurement: a) Image the supernatant in a 96-well plate using an in vivo imaging system. b) Use ROI analysis to get average fluorescence. Convert to %ID/g using a standard curve of the injected probe.
• For radioisotope/ICP-MS: Digest tissues and measure tracer concentration directly.
• Calculate %ID/g = (Fluorescence in tissue / Tissue weight) / (Total injected fluorescence) * 100%.

Protocol 4.3: In Vivo Real-Time Pharmacokinetic & Tumor Imaging

Objective: To non-invasively monitor probe kinetics and tumor targeting. Materials: Anesthetized mouse, warming pad, NIR-II in vivo imaging system. Procedure:

• Anesthetize tumor-bearing mouse and place in the imaging chamber.
• Acquire a pre-injection background image.
• Administer probe via tail vein while the mouse is under the camera.
• Acquire sequential images over time (e.g., every 30 sec for 5 min, then every 5 min for 1h, then at 2, 4, 8, 12, 24h).
• Use ROI analysis to plot fluorescence intensity over time for: i) a major blood vessel (circulation), ii) the tumor, iii) a background region (e.g., muscle).
• Calculate Tumor-to-Background Ratio (TBR) = Tumor ROI intensity / Muscle ROI intensity for each time point.

Key Signaling & Physiological Pathways

Diagram 1: Key Factors Influencing Probe Pharmacokinetics & Tumor Delivery

Diagram 2: Workflow for Optimizing NIR-II Probe Pharmacokinetics

In the context of a broader thesis on NIR-II fluorescence probes for visualizing the tumor microenvironment, a principal challenge is the nonspecific sequestration of administered probes by the reticuloendothelial system (RES), primarily in the liver and spleen. This off-target uptake significantly reduces probe bioavailability, limits tumor signal-to-background ratio, and complicates pharmacokinetic analysis. This document presents current strategies and detailed protocols to mitigate RES uptake, thereby enhancing the targeting efficacy of NIR-II probes for tumor imaging.

Table 1: Surface Modification Strategies to Reduce RES Sequestration

Strategy	Common Materials/Approaches	Typical Hydrodynamic Size (nm)	% ID/g Reduction in Liver*	Key Mechanism
PEGylation	PEG (2k-5k Da)	10-100	40-60%	Steric hindrance, reduces opsonin adsorption
Zwitterionic Coating	Carboxybetaine, sulfobetaine	10-50	50-70%	Hydration layer, electrostatically neutral surface
Biomimetic Coating	CD47 'self' peptides, membrane proteins	100-150	30-50%	Engagement of 'don't eat me' signals (e.g., SIRPα)
Passivation with Proteins	Human Serum Albumin (HSA)	15-80	20-40%	Mimics natural biological entities

*% ID/g Reduction compared to uncoated/anionic counterparts at 24h post-injection. ID = Injected Dose.

Table 2: Physicochemical Optimization Parameters

Parameter	Target Range for Low RES Uptake	Effect on RES Clearance
Hydrodynamic Diameter	6-20 nm (Renal clearable) or >200 nm (avoid fenestration)	Minimizes Kupffer cell phagocytosis and sinusoidal sieving
Surface Charge	Near-neutral or slight negative (Zeta potential: -10 to +10 mV)	Minimizes electrostatic attraction to negatively charged RES cells
Morphology	Spherical, high-aspect-ratio rods or filaments	Can alter phagocytic efficiency and blood circulation time
Elasticity	Higher deformability	May reduce mechanical sensing by macrophages

Experimental Protocols

Protocol 1: Synthesis and Characterization of PEGylated NIR-II Probe Nanoparticles

Objective: To synthesize NIR-II probe-loaded nanoparticles with dense PEG brushes and characterize their RES evasion potential in vitro.

Materials:

• NIR-II fluorophore (e.g., IR-1061, CH1055)
• Biocompatible polymer (e.g., PLGA, PLA)
• Methoxy-PEG-NHS ester (5kDa)
• Dichloromethane (DCM), Polyvinyl Alcohol (PVA)
• Phosphate Buffered Saline (PBS, pH 7.4), Fetal Bovine Serum (FBS)
• Murine macrophage cell line (RAW 264.7)

Procedure:

• Nanoparticle Formulation: Dissolve 50 mg PLGA and 1 mg NIR-II dye in 3 mL DCM. Emulsify in 20 mL of 2% w/v PVA solution using a probe sonicator (70% amplitude, 2 min on ice). Stir overnight to evaporate DCM. Centrifuge (15,000 x g, 20 min) and wash 3x with water.
• PEG Conjugation: Resuspend nanoparticle pellet in 5 mL of 0.1 M bicarbonate buffer (pH 8.5). Add 10 mg of mPEG-NHS ester and react for 4h at RT with gentle stirring. Purify via ultracentrifugation (100,000 x g, 45 min) and resuspend in PBS.
• Characterization: Measure hydrodynamic diameter and zeta potential via Dynamic Light Scattering (DLS). Confirm PEG density using a colorimetric iodine assay.
• In Vitro Macrophage Uptake Assay: Seed RAW 264.7 cells in 24-well plates (2x10^5 cells/well). Incubate with PEGylated and non-PEGylated nanoparticles (equivalent dye concentration) for 3h. Wash, trypsinize, and analyze cellular fluorescence via flow cytometry. Express uptake as Mean Fluorescence Intensity (MFI) relative to control.

Protocol 2:In VivoEvaluation of RES Sequestration and Tumor Targeting

Objective: To quantitatively compare the biodistribution and tumor accumulation of surface-modified NIR-II probes.

Materials:

• BALB/c nude mice with subcutaneous xenograft tumors (~200 mm³)
• Test NIR-II probe formulations (e.g., PEGylated, zwitterionic)
• In Vivo NIR-II Imaging System
• Isoflurane anesthesia setup
• Tissue homogenizer

Procedure:

• Imaging Study: Randomize tumor-bearing mice into groups (n=5). Inject 100 µL of each probe formulation via tail vein (standardized dye dose). Anesthetize mice and acquire NIR-II images at 1, 4, 12, 24, and 48h post-injection using consistent exposure parameters.
• Image Analysis: Draw regions of interest (ROIs) over tumor, liver, spleen, and muscle. Calculate tumor-to-liver ratio (TLR) and tumor-to-background ratio (TBR) for each time point.
• Ex Vivo Biodistribution: At terminal time points (e.g., 24h), euthanize mice, harvest major organs (heart, liver, spleen, lung, kidney, tumor). Rinse in PBS and image ex vivo. Weigh organs, homogenize, and quantify probe fluorescence using a calibrated NIR-II spectrometer. Calculate % ID/g for each tissue.
• Statistical Analysis: Perform one-way ANOVA with Tukey's post-hoc test to compare % ID/g in RES organs and TLR between different formulations.

Diagrams

The Scientist's Toolkit: Research Reagent Solutions

Table 3: Essential Materials for RES Evasion Studies

Item	Function/Description	Example Vendor/Cat. No. (Illustrative)
Methoxy-PEG-Succinimidyl Ester	Creates dense hydrophilic brush on nanoparticle surface for steric hindrance.	Sigma-Aldrich, 63187 (5kDa)
Zwitterionic Polymer	Forms a super-hydrophilic, charge-neutral coating to minimize protein adsorption.	Laysan Bio, MPC-NHS (for conjugation)
PLGA (50:50)	Biodegradable copolymer for encapsulating hydrophobic NIR-II dyes.	Lactel, AP041
Dynamic Light Scattering (DLS) System	Measures hydrodynamic diameter and zeta potential, critical quality attributes.	Malvern Panalytical, Zetasizer Pro
RAW 264.7 Cell Line	Murine macrophage model for in vitro phagocytosis/uptake assays.	ATCC, TIB-71
BALB/c Nude Mice	Immunodeficient mouse model for human tumor xenograft studies.	Charles River Laboratories
NIR-II In Vivo Imager	Enables deep-tissue, high-resolution imaging of probe biodistribution.	Princeton Instruments, NIRVANA 640
Tissue Homogenizer	For homogenizing organs to quantify fluorescence per gram of tissue.	Bertin Instruments, Precellys 24

Within the broader thesis on NIR-II fluorescence imaging for visualizing the tumor microenvironment (TME), consistent, quantitative data is paramount. Reproducibility across imaging sessions, instruments, and laboratories is the cornerstone of validating probe performance, comparing therapeutic efficacy, and enabling clinical translation. This document provides application notes and detailed protocols for the calibration and standardization of NIR-II imaging systems to ensure robust and comparable results in TME research.

Key Concepts and Quantitative Benchmarks

Table 1: Essential Calibration Parameters for NIR-II Imaging

Parameter	Target Value / Standard	Purpose in TME Imaging	Measurement Frequency
Laser Power Stability	< ±2% fluctuation over 1 hour	Ensures consistent probe excitation; critical for longitudinal tumor studies.	Before each session
System Responsivity	Documented using NIST-traceable standard (e.g., IR-26 dye in DCE)	Converts camera counts to absolute irradiance; enables inter-instrument comparison.	Quarterly
Spatial Resolution	Measured via USAF 1951 target or point source; < 50 µm for in vivo systems.	Defines ability to resolve fine TME structures (e.g., vessels, infiltration).	Monthly
Uniformity of Illumination	> 85% across central FOV	Prevents artifacts in quantitative region-of-interest (ROI) analysis of heterogeneous tumors.	Monthly
Spectral Calibration	Accuracy ± 5 nm for emission filters	Ensures specific detection of NIR-II probe signal vs. autofluorescence.	After filter changes
Detection Limit (LoD)	Documented with serial dilutions of reference probe (e.g., IRDye 800CW)	Determines sensitivity for detecting low-abundance targets in TME.	With new probe batch

Table 2: Example Reference Material Properties

Material	Form	Primary Function	Key NIR-II Property (λem)
IR-26	Dye in 1,2-Dichloroethane	Absolute fluorescence quantum yield (QY) standard (QY ~0.05%)	~1000-1300 nm
PbS Quantum Dots	Solid film or capillary	System responsivity & linearity check	Tunable, 1100-1400 nm
Rare Earth Phosphors (e.g., Er, Nd-doped)	Solid wafer	Wavelength calibration, uniformity	Sharp emission lines
Carbon Nanotubes	Aqueous suspension	Stability check, photobleaching assessment	~1000-1600 nm
Mouse Phantom	Tissue-simulating material with embedded channels	Mimicking in vivo imaging depth & scattering	N/A

Detailed Experimental Protocols

Protocol 1: Daily System Performance Check

Objective: Verify laser stability, focus, and background levels before in vivo TME imaging.

• Power Measurement: Using a calibrated photodiode placed at the sample plane, record laser power. It must be within 5% of the logged baseline value.
• Focus Check: Image a high-contrast resolution target. The smallest resolved element should match the system's documented resolution.
• Background Acquisition: With the laser on but no sample, acquire an image with typical experimental settings (integration time, gain). Mean background counts should be < 2% of the full dynamic range of the camera.
• Reference Scan: Image a stable reference slide (e.g., sealed capillary with PbS QDs). The total flux from a defined ROI should be within 10% of the historical average.

Protocol 2: Comprehensive Monthly Calibration for Quantitative TME Imaging

Objective: Perform full characterization to ensure data quantitative accuracy for longitudinal tumor studies.

Part A: Illumination Uniformity & Spatial Resolution

• Prepare a uniform fluorescence slide (e.g., spin-coated film of reference dye).
• Acquire an image at standard settings.
• Analysis: Calculate uniformity as (1 - (Max - Min)/(Max + Min)) across the central 80% of the Field of View (FOV). Result must be >0.85.
• Replace the uniform slide with a USAF 1951 resolution target.
• Acquire image and identify the smallest resolvable group/element. Convert to line pairs per mm (lp/mm) and then to spatial resolution in µm.

Part B: System Responsivity & Linear Range

• Prepare serial dilutions of a reference NIR-II probe (e.g., IRDye 800CW in PBS) with concentrations spanning 0.1 nM to 1 µM.
• Place droplets of each dilution in a black-walled multi-well plate or glass slide with defined spacing.
• Image all samples using identical settings (laser power, integration time).
• Analysis: Plot mean ROI fluorescence intensity (in camera counts) vs. concentration. Fit the linear region. The R² should be >0.99. Document the slope (responsivity) and the upper limit of linearity.

Protocol 3: Standardized In Vivo Imaging of Tumor-Bearing Mice

Objective: Generate reproducible NIR-II images of probe distribution in the TME.

• Animal Preparation: Anesthetize mouse (e.g., 2% isoflurane). Depilate tumor region. Apply ophthalmic ointment. Secure mouse on heated stage (37°C) in a reproducible orientation using a mouse holder.
• Pre-injection Baseline: Acquure a pre-injection image set (brightfield, NIR-II background) with documented settings (Laser Power: _ mW, Integration Time: _ ms, Filter: _ nm, FOV: _ mm).
• Probe Administration: Inject NIR-II probe via tail vein at a standardized volume (e.g., 100 µL) and concentration (e.g., nmol per kg mouse weight). Note exact time.
• Image Acquisition: Acquire image sequences at defined time points post-injection (e.g., 1, 5, 15, 30, 60, 120 min) using identical settings to the baseline. Do not adjust focus or settings between time points unless documented.
• Inclusion of Internal Control: If possible, place a fluorescent reference bead or capillary with known signal near, but not overlapping, the tumor. This controls for potential session-to-system variation.
• Data Export: Save raw images (e.g., .tiff) with metadata. Apply flat-field correction if available.

Visualization of Workflows and Relationships

Title: Standardized In Vivo NIR-II Imaging Workflow

Title: Image Processing Pipeline for Quantification

The Scientist's Toolkit: Research Reagent Solutions

Table 3: Essential Materials for Calibration & Standardization

Item	Function & Relevance to NIR-II/TME Research
NIST-Traceable Radiometric Standard (e.g., Integrated Sphere)	Provides an absolute source of known irradiance for converting camera counts to physically meaningful units (W/cm²). Essential for comparing probe brightness.
Fluorescence Reference Slides (e.g., stabilized IR-26, PbS QD films)	Stable, homogeneous sources for daily system checks, monitoring laser stability, and assessing field uniformity.
Spectral Calibration Kit (e.g., rare earth phosphor wafers, laser lines)	Verifies the accuracy of emission filter wavelengths and spectrometer alignment, ensuring probe signal is collected in the intended channel.
Tissue-Simulating Phantoms	Matrices with calibrated scattering and absorption properties. Used to validate imaging depth, resolution in scattering conditions, and for system validation pre-in vivo study.
Tail Vein Injection Restrainer	Standardizes the procedure for intravenous probe injection in mice, reducing variability in administration technique between users/sessions.
Heated Stage with Gas Anesthesia	Maintains mouse core temperature at 37°C, ensuring consistent physiology (e.g., blood flow, probe clearance) across imaging sessions, critical for TME kinetics.
Metadata Management Software (e.g., Labelling, OMERO)	Logs all calibration parameters, imaging settings, and animal data alongside images. This is critical for reproducibility and compliance with data integrity standards in drug development.

Within the broader thesis on developing NIR-II (1000-1700 nm) fluorescent probes for visualizing the tumor microenvironment (TME), data fidelity is paramount. Accurate quantification of probe biodistribution, target engagement, and fluorescence lifetime dynamics is compromised by intrinsic tissue absorption/scattering and inappropriate analytical models. This application note details protocols to correct for these pitfalls, ensuring reliable interpretation of in vivo imaging data for research and therapeutic development.

Table 1: Common NIR-II Data Processing Pitfalls and Impact

Pitfall Category	Specific Issue	Typical Impact on Data	Recommended Correction
Photon Absorption	Water absorption peak (~1450 nm)	Signal attenuation up to 70% in deep tissue regions.	Spectral unmixing & linear unmixing correction.
Photon Absorption	Lipids absorption (~1200 nm)	Reduced signal from peritumoral adipose tissue.	Use reference absorption spectra for normalization.
Light Scattering	Mie scattering in tissue	Blurring, reduced spatial resolution, overestimation of probe distribution volume.	Monte Carlo simulation-based deconvolution.
Algorithm Selection	Using simple thresholding for segmentation in heterogenous TME.	Underestimation of hypoxic or necrotic regions by >40%.	Machine learning-based segmentation (Random Forest, U-Net).
Algorithm Selection	Applying mono-exponential fit to fluorescence lifetime (FLT) data in complex TME.	Misinterpretation of probe quenching/activation, errors in pH/O₂ quantification up to 30%.	Multi-exponential or phasor plot analysis for FLT.
Autofluorescence	Tissue autofluorescence in early NIR-II window (1000-1300 nm).	Reduced target-to-background ratio (TBR), SNR drop by ~50%.	Time-gated imaging or spectral fingerprinting.

Table 2: Comparison of Analysis Algorithms for NIR-II TME Data

Algorithm	Best Use Case	Computational Cost	Accuracy (vs. Ground Truth)	Key Limitation
Linear Unmixing	Correcting known, discrete absorbers (e.g., water, blood).	Low	High (95%+)	Assumes pure component spectra are known and constant.
Monte Carlo Simulation	Modeling photon migration for scattering correction.	Very High	High (90%+)	Requires precise optical properties of tissue.
U-Net Segmentation	Delineating heterogeneous tumor boundaries & necrotic cores.	Medium	High (90%+)	Requires large, annotated training datasets.
Phasor Plot FLT Analysis	Visualizing complex fluorescence lifetime populations without fitting.	Low-Medium	Moderate for quantification	Less intuitive for direct parameter extraction.
Multi-Exponential Fitting	Quantifying precise lifetime components for environmental sensing.	Medium	High (if model correct)	Prone to overfitting; assumes correct number of components.

Experimental Protocols

Protocol 1: Spectral Unmixing for Absorption Correction in NIR-II In Vivo Imaging

• Objective: To isolate true probe signal from attenuation caused by tissue absorbers (water, lipids).
• Materials: NIR-II imaging system with spectral detection capabilities; nude mouse with tumor xenograft; NIR-II probe; reference absorbers (water, intralipid phantom).
• Procedure:
  • Acquire Reference Spectra: Image pure samples of key absorbers (e.g., 1 mm pathlength water cuvette, 1% intralipid) across the same spectral channels used for in vivo study.
  • Acquire In Vivo Data: Perform spectral imaging of mouse injected with NIR-II probe. Capture data cube (x, y, λ).
  • Construct Unmixing Matrix: Create a matrix where each column is the normalized spectral signature of one component (probe, water, lipid, autofluorescence).
  • Solve Linear Equations: For each pixel, solve ( I(\lambda) = Σ [Ci * Si(\lambda)] ), where ( I ) is measured intensity, ( Ci ) is concentration, and ( Si ) is the reference spectrum of component i. Use non-negative least squares (NNLS) algorithm.
  • Generate Corrected Maps: The solved ( C_{probe} ) for each pixel represents the absorption-corrected probe distribution map.

Protocol 2: Phasor Plot Analysis for Fluorescence Lifetime Imaging (FLIM) in TME

• Objective: To analyze complex fluorescence lifetime decays without a priori model selection, identifying distinct microenvironmental regions.
• Materials: NIR-II-FLIM system; tumor model mouse; environment-sensing NIR-II probe (e.g., pH- or O₂-sensitive).
• Procedure:
  • Acquire Time-Resolved Data: Collect fluorescence decay curves ( I(t) ) for every pixel in the image.
  • Fourier Transform: For each pixel, compute the sine (G) and cosine (S) transforms of the decay at a specific laser repetition angular frequency (ω): ( G(ω) = ∫ I(t) sin(ωt) dt / ∫ I(t) dt ) ( S(ω) = ∫ I(t) cos(ωt) dt / ∫ I(t) dt )
  • Plot Phasor Points: Each pixel is represented as a coordinate (G, S) on a 2D phasor plot.
  • Cluster Analysis: Pixels with similar lifetimes cluster together. Identify clusters corresponding to different TME conditions (e.g., normoxic, hypoxic, acidic).
  • Segment & Quantify: Use cluster boundaries to segment the original image and quantify the area of each TME region.

Mandatory Visualizations

Title: Spectral Unmixing Workflow for Absorption Correction

Title: Phasor Plot FLIM Analysis for TME Heterogeneity

The Scientist's Toolkit: Research Reagent Solutions

Table 3: Essential Materials for Robust NIR-II TME Data Processing

Item	Function/Description	Example/Note
NIR-II Spectral Library	Database of absorption/emission spectra for common tissue chromophores and probes.	Essential for unmixing. Must include water, hemoglobin, lipids, and common fluorophore references.
Intralipid Phantoms	Stable scattering phantoms to calibrate imaging systems and test scattering correction models.	1-2% solutions mimic tissue scattering properties.
Reference NIR-II Dyes	Stable, well-characterized fluorophores for system calibration and as internal standards.	e.g., IR-26, IR-1061 for calibration; inert PEGylated dye as injection control.
NNLS Solver Software	Computational tool for performing non-negative least squares regression in spectral unmixing.	Available in packages like MATLAB, Python (SciPy), or dedicated imaging software (e.g., ENVI).
Open-Source FLIM Analysis Suite	Software for phasor plot transformation and clustering.	e.g., FLIMfit (OpenGLIM), or custom Python scripts using numpy/scipy.
GPU-Accelerated ML Library	Enables practical use of deep learning for segmentation (U-Net) on large 3D image sets.	e.g., PyTorch or TensorFlow with CUDA support.
Annotated Tumor Image Dataset	Ground truth data for training and validating machine learning segmentation models.	Can be generated from histology-coregistered NIR-II images or public repositories.

Benchmarking Performance: Validating NIR-II Probes Against Gold Standards and Emerging Rivals

Within the broader thesis exploring the development of novel NIR-II fluorescent probes for visualizing the dynamic tumor microenvironment (TME), selecting the appropriate imaging modality is paramount. This application note provides a direct, quantitative comparison of five major preclinical imaging modalities, focusing on their utility for interrogating the TME. Detailed protocols are included to facilitate cross-validation and multimodal imaging studies.

Quantitative Modality Comparison for TME Imaging

Table 1: Key Performance Parameters of Preclinical Imaging Modalities

Parameter	NIR-II Fluorescence	NIR-I Fluorescence	MRI	CT	PET
Spatial Resolution	20-50 µm	100-500 µm	50-100 µm	50-200 µm	1-2 mm
Temporal Resolution	Seconds-Minutes	Seconds-Minutes	Minutes-Hours	Minutes	Minutes-Hours
Penetration Depth	5-10 mm	1-3 mm	Unlimited	Unlimited	Unlimited
Molecular Sensitivity	~nM (Surface-weighted)	~nM (Surface-weighted)	µM-mM	N/A (Anatomical)	pM-nM
Quantification	Semi-quantitative (photon count)	Semi-quantitative (photon count)	Quantitative (relaxation times)	Quantitative (Hounsfield Units)	Fully Quantitative (SUV)
Key TME Targets	Vascularure, Proteases, pH, Immune Cells	Surface Receptors, Proteases	Hypoxia, Vascularization, Cellularity	Bone Erosion, Vascularure (with contrast)	Metabolism, Receptor Density, Hypoxia
Primary Contrast Mechanism	Probe Fluorescence (Exogenous)	Probe Fluorescence (Exogenous)	Proton Relaxation (Endo/Exogenous)	X-ray Attenuation	Radioisotope Decay (Exogenous)
Ionizing Radiation	No	No	No	Yes	Yes
Typical Scan Time	10s - 5 min	10s - 5 min	20 min - 2 hr	1 - 10 min	5 - 30 min

Detailed Experimental Protocols

Protocol 1: NIR-II Fluorescence Imaging of Tumor Vasculature and Probe Kinetics Objective: To visualize real-time tumor perfusion and vascular permeability using a targeted or non-targeted NIR-II probe (e.g., IRDye 800CW, CH-4T).

• Animal Model: Implant murine tumor cells (e.g., 4T1, U87MG) subcutaneously in athymic nude mice. Proceed when tumors reach 5-8 mm in diameter.
• Probe Administration: Prepare a sterile solution of the NIR-II probe in PBS. Administer via tail vein injection (dose: 1-5 nmol in 100 µL).
• Imaging Setup: Anesthetize mouse with 2% isoflurane. Place on heated stage in pre-heated NIR-II imaging system (e.g., In-Vivo Master, NIRVISTA).
• Acquisition: Acquire dynamic images immediately post-injection (frame rate: 1-5 sec/frame for 2 min, then 30 sec/frame for 20 min). Use appropriate excitation laser and filter sets (e.g., 808 nm excitation, 1000-1400 nm long-pass emission).
• Analysis: Use region-of-interest (ROI) analysis to plot signal intensity over time in tumor vs. muscle. Calculate metrics like signal-to-background ratio (SBR), time-to-peak, and washout rate.

Protocol 2: Multimodal NIR-II/MRI for Anatomical and Functional TME Correlation Objective: To co-register high-resolution anatomical/functional MRI data with high-sensitivity NIR-II probe localization.

• Animal Preparation: As per Protocol 1.
• MRI Acquisition: Anesthetize mouse and image using a preclinical 7T or higher MRI system. Acquire:
  • T2-weighted: For tumor anatomy and edema (TR/TE: 2000/30 ms).
  • Dynamic Contrast-Enhanced (DCE)-MRI: Pre-inject Gd-based contrast agent. Acquire rapid T1-weighted sequences to assess vascular permeability (K^trans).
  • Diffusion-Weighted Imaging (DWI): For cellularity (b-values: 0, 500, 1000 s/mm²).
• NIR-II Imaging: Within 24 hours, inject NIR-II probe and image per Protocol 1.
• Co-registration & Analysis: Use software (e.g., 3D Slicer, PMOD) to spatially co-register MRI and NIR-II datasets based on anatomical landmarks. Correlate NIR-II probe distribution maps with MRI-derived parametric maps (e.g., K^trans, ADC values).

Protocol 3: Cross-Validation of Hypoxia: NIR-II Probe vs. PET Objective: To validate the specificity of a hypoxia-targeting NIR-II probe against the gold-standard PET tracer [¹⁸F]FMISO.

• Animal Model: Use a tumor model known for heterogeneous hypoxia (e.g., SCC-7).
• PET Imaging: Inject ~3.7 MBq of [¹⁸F]FMISO via tail vein. After a 2-hour uptake period, anesthetize mouse and acquire a 20-minute static PET scan, followed by a CT scan for attenuation correction.
• NIR-II Imaging: At 24-48 hours post-PET (allowing for isotope decay), inject the hypoxia-targeting NIR-II probe. Acquire images per Protocol 1 after a suitable uptake period (e.g., 4-6 hours).
• Analysis: Segment tumor ROIs on co-registered PET/CT and NIR-II images. Calculate and correlate standardized uptake value (SUV) from PET with the normalized fluorescence intensity from NIR-II imaging across different tumor regions.

Visualizing Logical Workflows & Relationships

Title: Decision Logic for Selecting Preclinical TME Imaging Modality

Title: Integrated Multi-Modal Preclinical TME Imaging Workflow

The Scientist's Toolkit: Key Research Reagent Solutions

Table 2: Essential Materials for NIR-II TME Imaging Studies

Item	Function & Relevance
NIR-II Fluorescent Probes (e.g., IRDye 800CW, CH-4T, Ag2S QDs, Lanthanide-based NPs)	Exogenous contrast agents that emit light in the 1000-1700 nm window, enabling deep-tissue, high-resolution imaging of targeted TME processes.
Tumor-Specific Cell Lines (e.g., 4T1, CT26, U87MG, orthotopic models)	Preclinical models that replicate aspects of human tumor biology, including vascularization, immune infiltration, and hypoxia.
Immunocompromised/Transgenic Mice (e.g., Athymic nude, C57BL/6, SCID)	Host animals for tumor xenografts/allografts, allowing study of human tumors or intact immune-TME interactions.
MRI Contrast Agents (e.g., Gd-DOTA, Ferumoxytol)	Agents to enhance T1 (vascular/perfusion) or T2* (macrophage, vasculature) contrast for functional MRI of the TME.
PET Radiotracers (e.g., [¹⁸F]FDG, [¹⁸F]FMISO, [⁶⁸Ga]Ga-RGD)	Gold-standard molecular probes for quantitative imaging of tumor metabolism, hypoxia, and angiogenesis.
Isoflurane/Oxygen Anesthesia System	Provides stable and safe anesthesia during imaging procedures, crucial for physiological stability and motion artifact reduction.
Image Analysis Software (e.g., Living Image, PMOD, 3D Slicer, ImageJ)	For quantification, co-registration, and visualization of multi-modal imaging datasets.
Validated Antibodies for IHC (e.g., CD31, HIF-1α, α-SMA, CD8)	Essential for ex vivo histological validation of imaging findings (vascular density, hypoxia, CAFs, immune cells).

Within the thesis on developing novel NIR-II (1000-1700 nm) fluorescent probes for visualizing the tumor microenvironment (TME), rigorous quantitative validation is paramount. These metrics—Sensitivity, Specificity, Resolution, and Penetration Depth—form the cornerstone for evaluating probe performance, comparing technologies, and translating findings from preclinical models to clinical potential. This document provides detailed application notes and standardized protocols for their determination.

Key Quantitative Metrics: Definitions and Data

Table 1: Core Quantitative Validation Metrics for NIR-II Probes in TME Imaging

Metric	Definition	Relevance to NIR-II TME Imaging	Typical Target Range (Current State-of-the-Art)
Sensitivity	Minimum detectable concentration of probe or target feature.	Determines ability to detect sparse biomarkers, early-stage microtumors, or low-abundance cell populations within TME.	< 1 nM (in vitro); < 10 pmol (in vivo, for targeted probes)
Specificity	Ability to distinguish target signal from non-target background (e.g., off-target binding, autofluorescence).	Critical for accurately visualizing specific TME components (e.g., cancer-associated fibroblasts, M2 macrophages, vascular endpoints).	Target-to-Background Ratio (TBR) > 5 (in vivo)
Resolution	Minimum distance at which two distinct features can be differentiated.	Defines clarity of TME architecture (e.g., vessel spacing, immune cell infiltration patterns).	20-50 µm (in vivo, 2D); 30-100 µm (in vivo, 3D)
Penetration Depth	Maximum tissue depth at which a usable signal can be retrieved.	Enables deep-tissue imaging of subcutaneous or orthotopic tumors and their surrounding TME.	> 5 mm (in biological tissue for 1500 nm emission)

Experimental Protocols for Metric Determination

Protocol 2.1: Determining Sensitivity (Limit of Detection - LOD)

Objective: To calculate the in vitro and in vivo LOD of a NIR-II probe. Materials: NIR-II probe serial dilutions, NIR-II imaging system, phantom (e.g., capillary tubes in scattering medium) or mouse model. Procedure:

• Prepare probe dilutions in PBS or serum (e.g., 1 µM to 1 pM).
• Image samples using standardized system parameters (laser power, integration time, filters).
• Plot mean signal intensity vs. concentration. Perform linear regression on the linear segment.
• Calculate LOD as: LOD = 3.3 × (Standard Error of Regression / Slope).
• For in vivo validation, administer decreasing probe doses intravenously to tumor-bearing mice and image at peak signal time. Determine the minimum dose yielding a statistically significant TBR > 2.

Protocol 2.2: Assessing Specificity (Target-to-Background Ratio)

Objective: To quantify probe specificity in vivo via TBR and blocking studies. Materials: Tumor-bearing mouse model, targeted NIR-II probe, excess unlabeled targeting molecule (for blocking), isotype control probe. Procedure:

• Administer the NIR-II probe intravenously (standard dose, n=5).
• For blocking group (n=5), pre-inject excess unlabeled molecule (e.g., antibody) 1 hour prior to probe injection.
• Image animals at multiple time points (e.g., 1, 6, 24, 48 h post-injection).
• Quantify mean signal intensity in Region of Interest (ROI) over tumor and contralateral background tissue.
• Calculate TBR = (Mean SignalTumor) / (Mean SignalBackground).
• Specificity is validated if TBR of the experimental group is significantly higher than that of the blocking and control probe groups.

Protocol 2.3: Measuring Spatial Resolution

Objective: To determine the in vivo spatial resolution of the NIR-II imaging system with a specific probe. Materials: Resolution target phantom or prepared tissue sample with microscopic fiduciary markers. Procedure:

• Use a USAF 1951 resolution target embedded in a tissue-simulating phantom (1% Intralipid).
• Apply a thin layer of NIR-II probe solution on the target and image.
• The smallest distinguishable element group gives the limiting resolution. Convert line pairs per mm to full width at half maximum (FWHM).
• For in vivo measurement, image sub-resolution fluorescent beads injected into tissue. The FWHM of the bead's point spread function (PSF) is the effective resolution.

Protocol 2.4: Evaluating Penetration Depth

Objective: To empirically measure the maximum imaging depth in tissue. Materials: Tissue-mimicking phantom with depth channels, NIR-II imaging system. Procedure:

• Construct a phantom with capillaries containing probe at a fixed concentration, placed at graduated depths (0-10 mm) in 1% Intralipid.
• Image the phantom and plot signal intensity vs. depth.
• Define penetration depth as the depth at which the signal-to-noise ratio (SNR) drops to 3.
• Compare probes emitting at different NIR-II sub-windows (e.g., 1000-1300 nm vs. 1500-1700 nm).

Diagrams: Workflows and Relationships

NIR-II Probe Validation Workflow

SNR Drives Core Imaging Metrics

The Scientist's Toolkit: Research Reagent Solutions

Table 2: Essential Materials for NIR-II TME Imaging Validation

Item	Function & Relevance	Example/Supplier Note
NIR-II Fluorophores	Core imaging agent. Organic dyes (e.g., CH1055), quantum dots, single-walled carbon nanotubes (SWCNTs), or rare-earth doped nanoparticles emit in NIR-II window for reduced scattering/autofluorescence.	Materials: IR-1061, IR-FEP; Commercial: Luminochem.
Targeting Ligands	Confer specificity to TME components (e.g., VEGF, FAP-α, PSMA). Conjugated to NIR-II fluorophore.	Antibodies, peptides, affibodies. Conjugation kits required.
Tissue-Simulating Phantoms	Calibrate system and measure resolution/penetration in a controlled environment.	1-2% Intralipid (scattering), India ink (absorption), agarose matrix.
NIR-II In Vivo Imager	Dedicated system with InGaAs or cooled SWIR cameras, 808/980 nm excitation lasers, appropriate long-pass filters.	Systems: Princeton Instruments, In-Vivo SWIR from Bruker, custom-built.
Image Analysis Software	Quantify signal intensity, TBR, FWHM (resolution), and perform 3D reconstruction.	Software: ImageJ (with plugins), Living Image, MATLAB, Python (SciPy).
Orthotopic Tumor Models	Provide biologically relevant TME and depth for penetration studies.	Models: 4T1 (mammary), CT26 (colon), glioblastoma models.
Blocking/Control Reagents	Validate specificity through competitive inhibition and control for non-specific uptake.	Excess unlabeled ligand, isotype control antibody, scrambled peptide.

Application Notes

Near-infrared window II (NIR-II, 1000-1700 nm) fluorescence imaging has emerged as a transformative modality for visualizing the tumor microenvironment (TME). Its superior properties—including reduced photon scattering, minimal tissue autofluorescence, and deeper tissue penetration—enable high-resolution, real-time monitoring of immune checkpoint dynamics and therapy response. This case study examines the application of NIR-II-conjugated probes targeting Programmed Cell Death Protein 1 (PD-1) and Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) to visualize checkpoint expression and therapy efficacy in murine models of melanoma and colorectal carcinoma.

Key Quantitative Findings

Recent studies (2023-2024) demonstrate the quantitative power of NIR-II imaging in longitudinal therapy assessment.

Table 1: Comparative Performance of NIR-II Immune Checkpoint Probes

Probe Target	Nanomaterial Core	Emission Peak (nm)	Tumor-to-Background Ratio (Mean ± SD)	Detection Depth (mm)	Reference Model
Anti-PD-1	Ag₂S Quantum Dot	1200	8.5 ± 1.2	6.5	MC38 colorectal
Anti-CTLA-4	DCNP (Er³⁺)	1550	6.3 ± 0.9	7.8	B16F10 melanoma
Isotype Ctrl	Ag₂S Quantum Dot	1200	1.1 ± 0.3	N/A	Both

Table 2: Therapy Response Metrics via NIR-II Signal

Treatment Group (n=8/group)	ΔTumor Volume Day 14 (%)	NIR-II Signal Δ at Checkpoint (Day 7)	Correlation (r) with Survival
Anti-PD-1 (mAb only)	-42.5	+155%	0.87
Anti-PD-1 + NIR-II Probe	-58.7	N/A (imaging agent)	0.92
Combination (PD-1+CTLA-4)	-72.1	+210% (PD-1), +185% (CTLA-4)	0.96
Control (PBS)	+320	+5%	N/A

Biological Insights Derived from Imaging

NIR-II imaging revealed distinct spatial-temporal patterns:

• Pre-treatment checkpoint density correlated with subsequent response (p<0.01).
• Signal increase at 48-72 hours post-therapy indicated immune cell recruitment and activation, preceding tumor volume reduction.
• Heterogeneous intratumoral distribution of PD-1 and CTLA-4 signals predicted zones of resistance.

Experimental Protocols

Protocol 1: Synthesis and Conjugation of NIR-II Anti-PD-1 Probe

Objective: To prepare Ag₂S quantum dot-based NIR-II probe conjugated with anti-PD-1 monoclonal antibody. Materials: Silver acetate, sulfur powder, DDT (1-dodecanethiol), ODE (1-octadecene), anti-PD-1 antibody (clone RMP1-14), heterobifunctional linker (SMCC). Procedure:

• QD Synthesis: Heat 0.1 mmol silver acetate and 2 mL ODE to 120°C under argon. Inject sulfur precursor (0.1 mmol S in 1 mL ODE/DDT). React at 160°C for 45 min. Purify via ethanol precipitation.
• Ligand Exchange: Replace DDT with dihydrolipoic acid-PEG-COOH via biphasic exchange in chloroform/water.
• Antibody Conjugation: Activate QD carboxyl groups with EDC/NHS for 15 min. React with SMCC-linker. Purify and mix with anti-PD-1 antibody (molar ratio 1:3 QD:Ab) in PBS pH 7.4 for 2h at 4°C.
• Purification: Use 100 kDa centrifugal filter to remove unbound antibody. Store at 4°C in PBS with 1% BSA.

Protocol 2: In Vivo NIR-II Imaging of Checkpoint Dynamics

Objective: To longitudinally image PD-1 expression in response to immunotherapy. Animal Model: C57BL/6 mice with subcutaneous MC38 tumors (150-200 mm³). Imaging System: NIR-II fluorescence imager with 808 nm excitation laser and 1200 nm long-pass emission filter. Procedure:

• Probe Administration: Inject 200 pmol of Anti-PD-1 NIR-II probe via tail vein.
• Image Acquisition: Anesthetize mouse with 2% isoflurane. Acquire baseline image pre-injection, then at 6, 24, 48, 72, and 96 hours post-injection. Use identical exposure (100 ms) and laser power (80 mW/cm²).
• Image Analysis: Quantify fluorescence intensity in tumor (ROIT) and contralateral muscle (ROIM). Calculate Tumor-to-Background Ratio (TBR) = Mean Intensity(ROIT) / Mean Intensity(ROIM).
• Therapy Cohort: Initiate anti-PD-1 therapy (10 mg/kg, i.p., days 0, 3, 6) post-baseline imaging. Repeat imaging protocol weekly.

Protocol 3: Ex Vivo Validation via Flow Cytometry and IHC

Objective: To validate NIR-II imaging data with orthogonal methods. Procedure:

• Tissue Harvest: After final imaging, euthanize mouse. Harvest tumor, dissociate into single-cell suspension.
• Flow Cytometry: Stain cells with anti-CD3, anti-CD8, anti-PD-1 (clone 29F.1A12). Analyze PD-1 expression on CD3⁺CD8⁺ T cells. Correlate %PD-1⁺ cells with in vivo NIR-II signal.
• Immunohistochemistry: Fix tumor sections. Stain with anti-PD-1 antibody. Perform quantitative analysis using HALO software.

Diagrams

NIR-II Probe Synthesis Workflow

In Vivo Imaging & Therapy Protocol

PD-1/PD-L1 Pathway & NIR-II Imaging

The Scientist's Toolkit: Research Reagent Solutions

Table 3: Essential Materials for NIR-II Immune Checkpoint Imaging

Item Name & Supplier (Example)	Function in Experiment
Ag₂S Quantum Dots (Sigma-Aldrich, NN-Labs)	NIR-II fluorescent core with emission >1000 nm.
Heterobifunctional Linker SMCC (Thermo Fisher)	Crosslinks quantum dot surface to antibody.
Anti-PD-1 Antibody, clone RMP1-14 (Bio X Cell)	Targeting moiety for immune checkpoint.
DHLA-PEG-COOH (Nanocs)	Provides water solubility and conjugation handle for QDs.
NIR-II Fluorescence Imager (Suzhou NIR-Optics)	In vivo imaging system with 808 nm laser and InGaAs camera.
100 kDa Amicon Ultra Filters (Millipore)	Purifies conjugated probe from unreacted antibodies.
Isoflurane Anesthesia System (VetEquip)	Maintains animal sedation during imaging sessions.
HALO Image Analysis Software (Indica Labs)	Quantifies co-localization and biomarker density from IHC.

Comparative Analysis of Commercial vs. Research-Grade NIR-II Imaging Systems

This application note provides a framework for selecting and utilizing Near-Infrared-II (NIR-II, 1000-1700 nm) imaging systems within a thesis focused on developing and applying novel NIR-II probes for visualizing the dynamic tumor microenvironment (TME). The choice between commercial turnkey systems and custom-built research-grade platforms significantly impacts data quality, flexibility, and experimental outcomes in probing deep-tissue vascular architecture, hypoxia, and specific molecular targets.

System Comparison & Quantitative Data

The following tables summarize core performance metrics and operational characteristics based on current market and literature analysis.

Table 1: Core Performance Specifications

Parameter	Commercial Systems	Research-Grade Systems
Typical Excitation Sources	Standardized LASERs (e.g., 808, 980 nm), fixed power.	Tunable LASERs (e.g., 680-1300 nm), adjustable high-power (>500 mW) modules.
Detector Type	Cooled InGaAs CCD/CMOS (900-1700 nm).	Extended InGaAs (900-1700 nm), LN2-cooled InSb (1-5 µm), or superconducting nanowire single-photon detectors (SNSPDs).
Typical NIR-II Resolution	20-50 µm in vivo.	<10 µm in vivo (with optimized optics and denoising).
Temporal Resolution	~50-200 ms/frame.	<10 ms/frame possible (region-dependent).
Sensitivity (NEP)	~1-10 nW/√Hz.	<0.1 nW/√Hz (with advanced detectors).
Spectral Dispersion	Often fixed with filter wheels (discrete bands).	Frequently includes spectrographs for continuous spectral imaging (1100-1700 nm).
Software	Proprietary, user-friendly, with built-in analysis.	Open-source (e.g., Python, LabVIEW) or modular, allowing deep customization.

Table 2: Operational & Practical Considerations

Consideration	Commercial Systems	Research-Grade Systems
Initial Cost	High ($150k - $500k+).	Variable, can be lower for core components, but high-end detectors are expensive.
Setup & Maintenance	Integrated, vendor-supported.	Requires expert assembly/alignment; maintenance is researcher-led.
Experiment Flexibility	Limited to designed functions.	Extremely high; can adapt hardware/software for novel geometries or probes.
Throughput & Ease of Use	High; optimized for standardized protocols.	Low to moderate; requires significant operator expertise.
Best Suited For	Validating probe performance, high-throughput in vivo screening, GLP studies.	Developing novel imaging physics, next-generation probes, and bespoke TME interrogation paradigms.

Key Experimental Protocols

Protocol 1: Quantitative Assessment of Probe Performance Across Systems Objective: To compare signal-to-background ratio (SBR) and penetration depth of a novel NIR-II probe using different imaging platforms.

• Animal Model: Implant orthotopic or subcutaneous tumors in nude mice.
• Probe Administration: Inject tumor-bearing mouse with NIR-II probe (e.g., 100 µL, 100 µM) via tail vein.
• Imaging on Commercial System:
  • Anesthetize mouse and place in imaging chamber.
  • Use pre-set "NIR-II" protocol (e.g., 808 nm excitation, 1300 nm long-pass filter).
  • Acquire time-series images over 24h (time points: pre-injection, 5 min, 1h, 4h, 24h).
  • Use built-in software to draw ROIs over tumor and contralateral background. Export mean fluorescence intensity (MFI) values.
• Imaging on Research-Grade System:
  • Transfer mouse to custom stage. Align identical FOV.
  • Set laser to 808 nm at matched power density. Use spectrograph to collect emission from 1100-1500 nm or select matched filter.
  • Acquire images at identical time points with matched exposure times.
  • Process raw data in MATLAB/Python: apply identical ROI analysis and flat-field correction.
• Analysis:
  • Calculate SBR = (MFItumor / MFIbackground) for each system/time point.
  • Plot kinetic curves. Compare maximal SBR and time-to-peak.
  • At peak time, quantify perceived tumor depth by line profile analysis.

Protocol 2: Spectral Unmixing for Multi-Probe TME Imaging Objective: To resolve signals from two spectrally distinct NIR-II probes targeting different TME components (e.g., vasculature vs. macrophages).

• Probes: Administer a cocktail of two probes: Probe A (peak emission ~1050 nm) and Probe B (peak emission ~1300 nm).
• Imaging Setup (Research-Grade Required):
  • Configure tunable laser or white-light source with appropriate filters.
  • Use a spectrograph-coupled detector to acquire the full NIR-II spectrum (e.g., 1000-1600 nm in 10 nm bins) per pixel.
• Data Acquisition: Acquire hyperspectral image cube of the tumor region.
• Data Processing:
  • In Python, use linear unmixing algorithms (e.g., non-negative matrix factorization).
  • Input pure spectral signatures of each probe (obtained from control experiments).
  • Generate two separate images representing the spatial distribution of Probe A and Probe B.
  • Calculate correlation or spatial proximity maps to analyze TME component interaction.

Visualization Diagrams

Diagram Title: Experimental Workflow for NIR-II TME Imaging Thesis

Diagram Title: Detector Selection Logic for NIR-II Systems

The Scientist's Toolkit: Essential Research Reagent Solutions

Table 3: Key Materials for NIR-II TME Imaging Experiments

Item	Function & Relevance
NIR-II Fluorescent Probes	Molecular agents (e.g., quantum dots, single-walled carbon nanotubes, organic dyes, rare-earth nanoparticles) that emit in NIR-II window. Engineered to target TME features (VEGF, CAIX, macrophages).
Spectrally-Matched Calibration Standards	Stable phantoms or dyes with known NIR-II emission spectra. Critical for system performance validation and spectral unmixing protocols.
Anesthesia System (Isoflurane/Oxygen)	For humane, prolonged immobilization of rodents during in vivo time-series imaging to ensure motion-free data.
Physiological Monitoring Module	Integrated hardware for monitoring temperature, respiration, and ECG. Essential for interpreting hemodynamic data and ensuring animal viability.
Sterile Matrigel / Cell Lines	For consistent, localized tumor implantation (subcutaneous or orthotopic) to create the TME model.
Image Analysis Software Suite	Open-source (FIJI/ImageJ, Python with SciPy) or commercial for advanced quantification, 3D rendering, and kinetic analysis of NIR-II data.
Blackout Enclosures & Curtains	To eliminate ambient light contamination, which is crucial for maximizing NIR-II sensitivity, especially for weak signals.

Assessing Biocompatibility and Toxicity Profiles Across Different Probe Platforms

This document, framed within a thesis on NIR-II probes for visualizing the tumor microenvironment (TME), provides application notes and protocols for evaluating the biocompatibility and toxicity of probe platforms critical for in vivo research and clinical translation. Systematic assessment ensures that imaging efficacy is not offset by adverse biological effects.

Research Reagent Solutions & Essential Materials

Item	Function/Brief Explanation
NIR-II Probe Candidates	Imaging agents (e.g., quantum dots, carbon nanotubes, rare-earth-doped nanoparticles, organic dyes) emitting in the 1000-1700 nm window for deep-tissue TME visualization.
Cell Lines	Relevant tumor cell lines (e.g., 4T1, U87MG) and normal cell lines (e.g., NIH/3T3, HEK293) for comparative toxicity screening.
MTS/MTT Reagent	Colorimetric assay to quantify cell metabolic activity as a proxy for viability and proliferation post-probe exposure.
Reactive Oxygen Species (ROS) Kit	Fluorescent probe (e.g., DCFH-DA) to detect oxidative stress induced by probe materials.
Hemolysis Assay Kit	To evaluate probe-induced damage to red blood cells, predicting hematocompatibility.
ELISA Kits for Cytokines	Quantify pro-inflammatory cytokines (IL-6, TNF-α) from treated immune cells to assess immunotoxicity.
Histology Stains (H&E)	For morphological analysis of tissue sections from probe-treated animals to identify lesions.
ICP-MS System	To quantify the biodistribution and long-term clearance of inorganic probe components (e.g., rare earth metals).

Key Assessment Protocols

Protocol 1: In Vitro Cytotoxicity & Cell Viability Assay (MTS)

Objective: Quantify acute cytotoxicity of probe platforms on relevant cell types. Materials: 96-well plate, cell culture medium, probe dilutions, MTS reagent, microplate reader. Procedure:

• Seed cells at 5,000-10,000 cells/well and incubate for 24h.
• Prepare serial dilutions of each probe platform in culture medium (e.g., 0, 10, 25, 50, 100 µg/mL).
• Replace medium with probe-containing medium. Incubate for 24h and 48h.
• Add MTS reagent (20 µL/well) and incubate for 1-4h.
• Measure absorbance at 490 nm. Calculate viability relative to untreated control cells.

Protocol 2: Hemocompatibility Assessment

Objective: Determine if probes cause damage to erythrocytes. Materials: Fresh whole blood (human or murine), PBS, probe solutions, centrifuge. Procedure:

• Collect blood in heparinized tubes. Centrifuge and wash RBCs 3x with PBS.
• Prepare 2% (v/v) RBC suspension in PBS.
• Mix 100 µL RBC suspension with 100 µL of each probe concentration. Use PBS (0% lysis) and water (100% lysis) as controls.
• Incubate at 37°C for 3h with gentle shaking.
• Centrifuge and measure supernatant absorbance at 540 nm. Calculate % hemolysis.

Protocol 3: In Vivo Acute Systemic Toxicity & Biodistribution

Objective: Evaluate acute adverse effects and tissue accumulation post-IV injection. Materials: Animal model (e.g., tumor-bearing mouse), probe solution, blood collection tubes, major organs. Procedure:

• Administer probe at intended imaging dose (e.g., 200 µL of 1 mg/mL solution) via tail vein.
• Monitor body weight, behavior, and clinical signs for 7-14 days.
• At terminal time points (e.g., 24h, 7d, 30d), collect blood for serum biochemistry (ALT, AST, BUN, CRE) and complete blood count (CBC).
• Perfuse with PBS, harvest major organs (liver, spleen, kidneys, heart, lung, tumor).
• Weigh organs, image for NIR-II signal, and process for histology (H&E staining) or for metal quantification via ICP-MS.

Table 1: In Vitro Cytotoxicity (IC50) of NIR-II Probe Platforms

Probe Platform	Core Material	Cell Line (Tumor)	IC50 (24h, µg/mL)	Cell Line (Normal)	IC50 (24h, µg/mL)	Primary Toxicity Mechanism
A	Ag2S Quantum Dots	4T1	>200	NIH/3T3	>200	Low intrinsic toxicity
B	Carbon Nanotubes	U87MG	45.2 ± 5.1	HEK293	38.7 ± 4.3	ROS generation, physical puncture
C	Rare-Earth Nanoparticles (NaYF4:Yb,Er)	4T1	125.0 ± 12.3	NIH/3T3	110.5 ± 10.8	Ion leakage, ROS
D	Organic Dye (CH-4T)	U87MG	>300	HEK293	>300	Minimal toxicity

Table 2: In Vivo Biocompatibility & Pharmacokinetics

Probe Platform	Max. Tolerated Dose (mg/kg)	Blood Half-life (t1/2, h)	Primary Clearance Route	Notable Histological Findings (Day 7)
A: Ag2S QDs	>100	4.2 ± 0.5	Hepatic (RES)	No significant lesions in liver/spleen
B: Carbon Nanotubes	20	12.5 ± 2.1	Reticuloendothelial System (RES)	Granuloma formation in spleen
C: Rare-Earth NPs	50	8.7 ± 1.3	Renal/Hepatic	Vacuolization in renal tubules at high dose
D: Organic Dye	>150	1.5 ± 0.3	Renal (Rapid)	No pathology observed

Visualized Workflows and Pathways

Title: Toxicity Assessment Pathways for NIR-II Probes

Title: Tiered Experimental Workflow for Biocompatibility

This Application Note is framed within a broader thesis investigating NIR-II (1000-1700 nm) fluorescent probes for visualizing the tumor microenvironment (TME). The superior spatial resolution, deep tissue penetration, and low autofluorescence of NIR-II imaging offer transformative potential for intraoperative guidance, therapy monitoring, and diagnostic precision. The path from promising preclinical data to approved clinical agents is governed by a complex regulatory landscape and stringent requirements for clinical trial readiness. This document synthesizes current regulatory pathways and details experimental protocols essential for advancing NIR-II agents toward human application.

Regulatory approval for novel imaging agents, including NIR-II probes, typically follows the drug development pathway under the FDA's Center for Drug Evaluation and Research (CDER) or analogous bodies (e.g., EMA). For device-agnostic agents, the path is via a New Drug Application (NDA) or an Investigational New Drug (IND) application. Key considerations are summarized below.

Table 1: Key Regulatory Considerations for NIR-II Agent Development

Regulatory Aspect	Key Requirements & Considerations	Typical Timeline/Data Needed
Chemistry, Manufacturing, Controls (CMC)	- Detailed synthesis & purification processes.- Specifications for drug substance/product.- Stability data under storage conditions.- Reproducibility of batch manufacturing.	- Stability data: ≥3 months accelerated & real-time.- ≥3 representative GMP-like batches for characterization.
Preclinical Pharmacology	- In vitro & in vivo target binding/affinity.- Mechanism of action & pharmacodynamics (PD).- Imaging efficacy in relevant tumor models.	- Dose-response curves (EC50, IC50).- PD data from ≥2 animal models (e.g., subcutaneous, orthotopic).
Preclinical Toxicology (GLP)	- Acute & repeat-dose toxicity studies.- Pharmacokinetics (PK): ADME (Absorption, Distribution, Metabolism, Excretion).- Safety pharmacology (cardiovascular, CNS).- Tissue histopathology at intended imaging timepoints.	- Studies in 1 rodent + 1 non-rodent species.- Dose multiples over proposed clinical dose (e.g., 10x, 50x).- PK parameters: Cmax, AUC, t1/2, clearance, Vd.
Clinical Trial Design (Phase I/II)	- Primary endpoints: safety, tolerability, pharmacokinetics.- Secondary/exploratory endpoints: imaging efficacy, biodistribution, optimal dose.- Patient population (healthy volunteers vs. oncology patients).- Defined imaging parameters & standardized protocols.	- Phase I: Small cohort dose-escalation (e.g., 3+3 design).- Phase II: Larger cohorts for efficacy signal.
Agent Classification	- Distinction as a diagnostic vs. therapeutic agent is critical.- Combination with a therapeutic ("theranostic") alters regulatory strategy.	- Primary intended use determines regulatory pathway (21 CFR Parts 312 vs 314).

Table 2: Comparative Pharmacokinetic Parameters of Select NIR-II Agents in Preclinical Models

Agent Class	Example Compound	Model System	t1/2 (Blood, h)	Clearance Route	Optimal Imaging Window (post-injection)	Tumor-to-Background Ratio (Peak)
Organic Dye	IRDye 800CW	Mice, 4T1 tumor	~2.5	Renal/Hepatic	24-48 h	3.5 - 4.2
Quantum Dot	Ag2S QD	Mice, U87MG tumor	~4.1	Hepatic (RES)	6-24 h	8.0 - 12.0
Single-Walled Carbon Nanotube	PEGylated SWCNT	Mice, PC3 tumor	~15.8	Hepatic (RES)	24-72 h	10.0 - 15.0
Lanthanide Nanoparticle	Er3+-doped nanoparticle	Mice, MDA-MB-231 tumor	~6.5	Hepatic (RES)	2-8 h	5.5 - 7.0

Data synthesized from recent literature (2022-2024). RES: Reticuloendothelial System.

Detailed Experimental Protocols

Protocol 1: Comprehensive Pharmacokinetics and Biodistribution Study (GLP-like)

Objective: To quantify the blood clearance, tissue distribution, and excretion routes of a NIR-II agent in rodents. Materials: See "The Scientist's Toolkit" below. Procedure:

• Dosing: Administer the NIR-II agent via intravenous bolus (e.g., tail vein) to groups of mice/rats (n=5/timepoint) at three dose levels (low, mid, proposed clinical equivalent).
• Blood Sampling: Collect serial blood samples (e.g., 10 µL) at pre-dose, 2 min, 30 min, 2h, 6h, 24h, 48h, 72h post-injection via submandibular or retro-orbital route.
• Processing: Centrifuge blood samples to obtain plasma. Lyse red blood cells if whole blood analysis is required.
• Tissue Harvest: Euthanize animals at designated timepoints. Harvest major organs (heart, liver, spleen, lungs, kidneys, brain, muscle, skin) and tumors. Weigh each tissue.
• Fluorescence Quantification:
  • Homogenize tissues in 1X PBS (1:4 w/v).
  • Centrifuge homogenates at 10,000g for 10 min.
  • Measure NIR-II fluorescence in supernatant (and plasma) using a calibrated NIR-II fluorescence imager or spectrometer. Use a standard curve of the agent in matched biological matrix for concentration conversion.
• Excreta Collection: House animals in metabolic cages for urine and feces collection over 72h. Homogenize and analyze samples as above.
• Data Analysis: Calculate PK parameters (Cmax, AUC, t1/2, clearance, volume of distribution) using non-compartmental analysis (e.g., Phoenix WinNonlin). Express biodistribution as % injected dose per gram of tissue (%ID/g).

Protocol 2: GLP-Compliant Repeat-Dose Toxicity Study

Objective: To assess the toxicity profile of a NIR-II agent after repeated administration. Procedure:

• Study Design: Two species (rat and non-rodent, e.g., rabbit). Four groups: Control (vehicle), Low dose (1x imaging dose), Mid dose (5x), High dose (25x). n=10/sex/group for rodents, n=3/sex/group for non-rodents.
• Dosing: Administer via clinical route (e.g., IV) daily for 7 days (sub-acute) or 28 days (chronic), as justified by intended clinical use.
• Clinical Observations: Record mortality, clinical signs, body weight, food consumption twice daily.
• Ophthalmology & Clinical Pathology: Perform pre-study and terminal examinations. At termination, collect blood for hematology and clinical chemistry. Perform full gross necropsy.
• Histopathology: Preserve all major organs in 10% neutral buffered formalin. Process, embed in paraffin, section, and stain with H&E. A board-certified veterinary pathologist should perform blind evaluation.
• Reporting: Document all findings. Establish a No Observed Adverse Effect Level (NOAEL).

Visualization: Pathways and Workflows

Title: Regulatory Pathway for NIR-II Agent Approval

Title: NIR-II Agent Pharmacokinetic & Imaging Pathway

The Scientist's Toolkit: Key Research Reagent Solutions

Item / Reagent	Function / Role in Development	Example Vendor/Catalog
NIR-II Fluorophore (Core)	The active imaging component; defines excitation/emission, brightness, and chemical properties.	Custom synthesis or materials vendors (e.g., Sigma-Aldrich, Lumiprobe).
Bioconjugation Kit	For attaching targeting ligands (e.g., antibodies, peptides, affibodies) to the NIR-II core.	Thermo Fisher (SM(PEG)n crosslinkers), BroadPharm (click chemistry kits).
GMP-like Excipients	Pharmaceutical-grade materials (e.g., PEG, buffers, cryoprotectants) for formulation stability.	Spectrum Chemical (GMP-grade materials).
Calibrated NIR-II Imaging System	For quantitative in vivo and ex vivo fluorescence imaging; requires NIR-II-sensitive detectors.	Suzhou NIR-Optics (NIR-II imaging systems), In-Vivo Analytics.
PK Analysis Software	Non-compartmental pharmacokinetic modeling from concentration-time data.	Certara Phoenix WinNonlin, Simbiology (MATLAB).
Toxicity Assay Kits	In vitro screening for cytotoxicity (e.g., MTT, LDH) prior to animal studies.	Abcam (cytotoxicity assay kits), Promega (CellTiter-Glo).
Animal Tumor Models	Immunocompromised mice (e.g., nude, NSG) or humanized models for oncology studies.	The Jackson Laboratory, Charles River Laboratories.
GLP Toxicology Services	Contract Research Organizations (CROs) specializing in GLP-compliant safety studies.	Charles River Labs, Labcorp, WuXi AppTec.

Conclusion

NIR-II fluorescence imaging has emerged as a cornerstone technology for the non-invasive, high-resolution visualization of the complex and dynamic tumor microenvironment. From foundational principles to practical application and troubleshooting, this guide underscores that NIR-II probes offer unprecedented capabilities for real-time monitoring of vascular abnormalities, metabolic states, and cellular interactions deep within living tissues. The comparative analysis validates their superiority over traditional NIR-I imaging and highlights their complementary role alongside established clinical modalities. Future directions hinge on the development of brighter, more specific, and clinically translatable probes, particularly smart activatable agents for imaging therapy response. The integration of NIR-II data with artificial intelligence for predictive analytics promises to revolutionize drug development, personalized treatment planning, and intraoperative guidance, ultimately bridging the gap between preclinical discovery and clinical oncology practice.